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ABSTRACT
CO-TREATMENT WITH CONJUGATED LINOLEIC ACID AND NITRITE
MODULATES MITOCHONDRIAL RESPIRATION AND ELECTRON
TRANSPORT CHAIN ACTIVITY IN VIVO AND ATTENUATES
MITOCHONDRIAL DYSFUNCTION DURING CARDIAC INJURY

Patrick Van Hoose
November 17th, 2015

Cardiovascular

disease

and

subsequent

complications,

such

as

myocardial infarction (MI), is the leading cause of death within the United States.
Clinical intervention to reduce cardiac damage following myocardial ischemia is
limited. Polyunsaturated fatty acids have been linked to an overall beneficial
effect on cardiovascular health and function. Conjugated linoleic acid (cLA) is an
18:2 unsaturated fatty acid found within the diet in ruminant meat and dairy
products. The cis-9 trans-11 isomer of cLA is the most prominent isomer within
the diet and cLA has been linked to favorable outcomes in numerous disease
states. The mechanism mediating the effects of cLA are still unclear but
mitochondria appear to be playing a prominent role. Nitrite (NO2-) is a dietary
source of nitric oxide (NO), as it is found within green leafy vegetables and it is
linked to cardioprotection in ischemia reperfusion injury models. Alterations in
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mitochondrial function and electron transport chain enzymatic activity have been
elucidated as the mechanisms mediating nitrite cardioprotection. However,
recent clinical trials have reported no positive outcome in patients undergoing MI
who have been supplemented with nitrite. A combination treatment of cLA and
nitrite preserves cardiac function following MI, highlighting that the interaction
between dietary constituents may influence cardioprotective effects. In the first
step of this study, we examine whether the combination treatment of cLA and
nitrite influenced mitochondrial respiration and electron transport chain activity
under baseline conditions. In the second step of this study, we examine the
impact of co-treatment with cLA and nitrite on mitochondrial function following MI
and aging. Under baseline conditions, we found that co-administration of cLA and
nitrite decreased mitochondrial respiration and complex III activity. Following MI,
the co-treatment of cLA and nitrite attenuated MI-induced increases in
mitochondrial respiration, complex III activity, and hydrogen peroxide levels.
However, following aging the co-treatment was unable to restore aging induced
mitochondrial dysfunction. These results demonstrate that in combination the
dietary constituents, cLA and nitrite, are able to influence mitochondrial function
under non-injury setting and following MI. Overall, this supports a role of
mitochondria in the cardioprotective effects mediated by a combination treatment
of cLA and nitrite.
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CHAPTER I

INTRODUCTION: CARDIOVASCULAR DISEASE, MITOCHONDRIA, AND
NITRATED FATTY ACIDS

Cardiovascular Disease Statistics

Cardiovascular disease (CVD) is the leading cause of death globally,
accounting for more than 17.3 million deaths annually and representing an
economic cost of $863 billion as of 2010 (1). CVD affects 85.6 million Americans
and represents approximately 31.3% of all deaths in the United States (US) (1).
The estimated direct and indirect cost of CVD within the US as of 2011 was
estimated at $320.1 billion and the direct cost of CVD is expected to increase to
over $918 billion by 2030 (1). Coronary heart disease (CHD) is the most common
type of CVD, making up approximately half of all CVD deaths. An estimated 15.5
million US adults have CHD and the morality associated with CHD was 375,295
in the U.S. in 2011(1). A common complication of CHD is myocardial infarction
(MI) and the estimated annual incidence of MI is 525,000 new attacks and
210,000 recurrent attacks within the U.S. (1).
Coronary heart disease is the result of atherosclerosis, a progressive
disease stemming from inflammation of intima of the coronary arteries leading to
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gradual thickening of the intima (2). Risk factors for coronary artery disease
include a high level of low density lipoproteins (LDL), high blood cholesterol
levels, family history, diabetes, obesity, smoking and age. Atherosclerosis can be
broken down into several stages: 1) endothelial dysfunction, 2) oxidized LDL and
macrophage accumulation, 3) foam cell formation and smooth muscle
recruitment, 4) vascularization, 5) necrotic core and 6) plaque rupture.
Endothelial dysfunction caused by low wall shear stress is a key initiation event
for atherosclerosis (3) leading to decreased nitric oxide (NO) and increased
chemokine and pro-inflammatory mediators (4). Increased expression of
adhesion molecules (5), the scavenger receptor CD-36 (6), and proteoglycans
(7) lead to recruitment of monocytes and oxidized LDL within the intima.
Monocytes differentiate into macrophages and ingest oxidized LDL forming foam
cells. Foam cells secrete pro-inflammatory cytokines and recruit smooth muscle
cells (3) to the intima which also take up lipids creating a lipid rich core within the
plaque. Neovascularization of the plaque by leaky vasculature from the
adventitial vasa vasorum leads to further monocyte recruitment (3) and increases
plaque size (8). Eventually the plaque forms a necrotic core due to macrophage
(9), foam cell and smooth muscle cell (3) apoptosis. The loss of smooth muscle
cell secretion of collagen, elastin, and proteoglycans leads to plaque cap
thinning. Cap thinning can lead to plaque rupture (10), exposing the
thromobogenic plaque core to platelets within blood, thereby initiating platelet
aggregation, vasoconstriction, and fibrin deposition (8), which leads to occlusion
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of a coronary artery (2). Disruption in blood and oxygen flow to the myocardium
results in MI, a major healthcare consequence of coronary heart disease.
MI is defined as myocardial cell death due to prolonged ischemia and is
the result of an imbalance between oxygen supply and demand (11). Ischemic
injury can be divided into three phases: 1) ischemic 2) reperfusion and 3)
reperfusion repair (12). The lack of oxygen of during ischemia results in
cardiomyocyte cell death via apoptosis and necrosis (13). Apoptosis is a
programmed cell death pathway characterized by membrane blebbing, cell
shrinkage, nuclear fragmentation and chromatin condensation (14). Apoptosis is
activated via two distinct pathways: the extrinsic and intrinsic pathway. The
extrinsic pathway is mediated by proinflammatory ligands such as tumor necrosis
factor alpha (TNF-) and tumor necrosis factor ligand super family member six
(15) which activate plasma membrane receptors. The intrinsic pathway is
mediated by release of mitochondrial death factors including cytochrome c, high
temperature requirement A2 (HtrA2) apoptosis inducing factor and second
mitochondrial derived activator of caspase (SMAC). The downstream target of
both the intrinsic and extrinsic pathways is caspase-3, a cysteine protease, which
degrades proteins and activates deoxyribonucleases (DNases) to degrade
deoxyribonucleic acid (DNA) (14). Apoptosis is an energy requiring process so
cardiomyocytes within the border zone of the infarct undergo apoptosis and
cardiomyocytes within the infarct zone undergo necrosis due to depletion of
adenosine triphosphate (ATP).
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Necrosis involves whole cell swelling and loss of plasma membrane
integrity (14) resulting from decreased ATP levels needed to maintain ionic
gradients at the plasma membrane. Upon plasma membrane rupture cellular
contents initiate an inflammatory response within the myocardium resulting in
migration of macrophages, monocytes, and neutrophils into the infarct zone (16).
Macrophages secrete growth factors leading to conversion of fibroblasts to
myofibroblasts that secrete collagen to preserve ventricular integrity. The hypoxic
environment occurring during MI sets the stage for cell death and reperfusion of
ischemic cardiac tissue is necessary to salvage the myocardium; however,
reperfusion also contributes to injury (17). The reoxygenation of myocardium
results in significant generation of reactive oxygen species (ROS) which can
trigger inflammation and damage proteins, lipids, and DNA, ultimately leading to
cellular dysfunction and death. ROS generation within the myocardium also plays
a protective role by generating growth factors that promote angiogenesis,
promoting

activation

of

vascular

smooth

muscle

cells

and

matrix

metalloproteinases (MMPs) that are necessary for the reparative phase (12).
MMPs degrade intermyocyte collagen thereby expanding the infarct resulting in
ventricular dilation leading to ventricular dysfunction (18). Overall, MI leads to a
complex adaptive response, resulting in an attempt to salvage myocardium and
preserve heart function. However, the end result of MI is cardiac dysfunction.
Two prevailing details of MI induced cardiac dysfunction, cardiomyocyte cell
death and ROS generation, share a common link: mitochondria.
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Mitochondria
History
Mitochondria arose from bacteria and developed a symbiotic relationship
within cells (19). Mitochondria are membrane organelles contained within cells
that carry out fundamental metabolism reactions necessary for cell survival.
Mitochondria can also initiate apoptosis placing mitochondria at the interface
between cell survival and cell death. The citric acid cycle (TCA cycle), betaoxidation of fatty acids and oxidative phosphorylation via the electron transport
chain occur within mitochondria and these are essential metabolic pathways
providing energy for the cell.

Function
Citric acid cycle

The TCA cycle was proposed by Hans Adolf Krebs in 1937 and is an
oxidative pathway for the metabolism of carbohydrates, fats and amino acids.
Eight enzymes comprise the TCA cycle that results in the oxidation of acetylCoenzyme A (acetyl-CoA) resulting in production of three nicotinamide adenine
dinucleotide reduced form (NADH), one flavin adenine nucleotide reduced form
(FADH2), and one guanosine triphosphate (GTP) (20). The first reaction of the
TCA cycle is the condensation of acetyl-CoA with oxaloacetate catalyzed by
citrate synthase producing citrate. Citrate is then isomerized to isocitrate by
aconitase and isocitrate is converted to alpha ketogluturate by isocitrate
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dehydrogenase generating one NADH. Alpha ketoglutarate dehydrogenase then
performs an oxidative decarboxylation reaction converting alpha ketoglutarate to
succinyl-CoA, producing one NADH. Succinyl-CoA then undergoes a reaction
with succinic thiokinase producing one GTP. Succinate dehydrogenase then
converts succinate to fumarate producing FADH2 and this is followed by
hydration of fumarate to malate by fumarase. The last reaction of the TCA cycle
is the dehydrogenation of malate by malate dehydrogenase producing
oxaloacetate, which can undergo condensation with another acetyl-CoA thereby
starting another round of the TCA cycle. The NADH and FADH2 produced during
the TCA cycle can donate electrons to the electron transport chain contributing to
the production of adenosine triphosphate (ATP) via oxidative phosphorylation. An
important source of acetyl-CoA for the TCA cycle is the beta oxidation of fatty
acids.

Beta Oxidation of Fatty Acids

Fatty acids enter into mitochondria via the carnitine palmitoyl carrier
protein in which carnitine palmitoyl transferase I removes the CoA group on the
fatty acid and attaches a carnitine moiety to a free fatty acid in the cytosol, which
allows the fatty acid to pass through the carnitine carrier protein. Once inside the
mitochondrial matrix, the carnitine moiety is removed by carnitine palmitoyl
transferase II, and the CoA is reattached to the fatty acid. The beta oxidation of
fatty acids occurs via four reactions catalyzed by acyl-CoA dehydrogenase,

6

enoyl-CoA hydratase, 3-L-hydroxyl-CoA dehydrogenase, and B-ketoacyl-CoA
thiolase. Acyl-CoA dehydrogenase catalyzes dehydrogenation of the fatty acylCoA creating a trans-alpha-beta double bond with the subsequent generation of
FADH2, which enters the ETC via the electron-transfer flavoprotein (ETF) and the
ETF:ubiquinone oxidoreductase. Enoyl-CoA hydratase then catalyzes the
hydration

of

the

trans-alpha-beta

bond

followed

by NAD+ dependent

dehydrogenation by 3-L-hydroxyl-CoA dehydrogenase generating NADH, which
can enter into the ETC. B-ketoacyl-CoA thiolase cleaves the alpha and beta
carbon to form acetyl-CoA, which can enter the TCA cycle, and a new acyl-fatty
acid with two fewer carbon atoms, that can undergo another round of beta
oxidation.
Mitochondria also contain additional enzymes for the oxidation of
unsaturated fatty acids including: 1.enoyl-CoA isomerase, which re-positions a
beta-gamma double bond into an alpha-beta position, 2. 2,4-dienoyl-CoA
reductase and 3,2-enoyl-CoA isomerase, which catalyze the removal of a double
bond at an even numbered carbon and 3. 3,5-2,4-dienoyl-CoA isomerase, which
catalyzes a reversible reaction that interconverts trans-2 and trans-3 double
bonds. Overall, one round of beta oxidation of fatty acids results in the production
of acetyl-CoA, a substrate for the TCA cycle and one each of FADH2 and NADH,
which can enter the ETC leading to the production of ATP.

Electron Transport Chain
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The electron transport chain (ETC) is embedded in the inner mitochondrial
membrane and is responsible for the majority of ATP production within the cell.
The ETC is composed of 5 different protein complexes: NADH-coenzyme Q
oxidoreductase (complex I), succinate-coenzyme Q oxidoreductase (complex II),
coenzyme Q-cytochrome c oxidoreductase (complex III), cytochrome c oxidase
(complex IV) and ATP synthase (complex V). Together complex I, II, III and IV
transfer electrons to oxygen (O2), the final electron acceptor while also pumping
hydrogen ions into the mitochondrial inner membrane space creating an
electrochemical gradient. ATP synthase uses this electrochemical gradient for
the phosphorylation of adenosine diphosphate (ADP) to ATP, thus the ETC
couples electron transport to oxidative-phosphorylation for the production of ATP
(Fig. 1).

Complex I
Complex I, comprised of 46 subunits, is an L-shaped protein with one arm
embedded in the inner mitochondrial membrane and the other arm extended into
the mitochondrial matrix. Complex I transfers electrons from NADH to coenzyme
ubiquinone (CoQ), a hydrophilic electron carrier within the mitochondrial inner
membrane. Complex I contains a flavin mononucleotide (FMN) and nine iron
sulfur clusters that participate in the transfer of electrons from NADH to CoQ via
a mechanism according to the reduction potential of the various redox centers
within complex I (21). FMN and CoQ can take up two oxidation states as both
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Figure 1. Electron transport chain.

Figure 1. Electron transport chain. The mitochondrial electron transport chain
is composed of complex I, II, III, IV and ATP synthase. Electrons are carried
down the chain to the final electron acceptor oxygen and protons are pumped by
complex I, III and IV. ATP synthase uses the proton gradient to convert ADP to
ATP.
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form stable semiquinone radicals allowing both to donate either one or two
electrons thus allowing NADH to transfer two electrons. In addition, to the
transfer of electrons complex I also pumps 4 hydrogen ions into the inner
membrane space contributing to the electrochemical gradient.

Complex II

Complex II contains the TCA cycle enzyme succinate dehydrogenase and
transfers electrons from succinate to CoQ. Complex II transfers electron from
succinate to FAD initially followed by passage through three iron sulfur clusters,
one cytochrome b560 and ultimately to CoQ. Complex II does not transverse the
inner mitochondrial membrane or translocate hydrogen ions (22).

Complex III

Complex III transfers electrons from reduced CoQ to cytochrome c while
pumping 4 hydrogen ions into the inner membrane space, via the Q cycle (23). In
the first step of the Q cycle, reduced CoQ binds to the Qo site where it transfers
one electron to the iron-sulfur protein (ISP), containing the Rieske center, while
releasing two protons into the inner membrane space. The ISP reduces
cytochrome c1, while CoQ semiquinone transfers its remaining electron to
cytochrome bL, a b-type cytochrome heme with low redox potential, yielding a
fully oxidized CoQ (23). Cytochrome bL then reduces cytochrome bH, a b-type
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cytochrome heme with high redox potential. The oxidized CoQ then is released
from the Qo site and binds to the Qi site and receives an electron from
cytochrome bH yielding CoQ semiquinone (24). This is the first cycle of the Q
cycle, resulting in two hydrogen ions pumped into the inner membrane space, a
reduced cytochrome c1 and a CoQ semiquinone. The second cycle of the Q
cycle, is identical to the first cycle, however the CoQ semiquinone produced in
the first cycle accepts an electron from cytochrome b H, along with two hydrogen
ions from the mitochondrial matrix to produce a reduced CoQ (24). The electrons
passed to cytochrome c1 are transferred to cytochrome c, a peripheral membrane
protein that shuttles electrons from complex III to complex IV (24).

Complex IV

Complex IV catalyzes one-electron oxidations of four cytochrome c
molecules to reduce one oxygen molecule to two water (H2O) molecules. Four
redox centers, cytochrome a, cytochrome a3, a copper atom known as CuB and a
pair of copper atoms known as the CuA center participate in electron transfer of
Complex IV (25). The transfer of electrons that occurs is linear from cytochrome
c to CuA, to cytochrome a, then finally to cytochrome a3 and CuB. The
cytochrome a3 and CuB are in close proximity to each other, almost forming a
single binuclear complex, where the reduction of O2 to H2O occurs. The
cytochrome a3 and CuB binuclear complex is reduced by two consecutive
electron transfers from cytochrome c via cytochrome a and Cu A, with the release
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of H2O (25). Molecular oxygen binds to the heme of cytochrome a3 followed by
internal electron redistribution in which tyrosine 244 of Cu B has donated an
electron and proton to the heme cytochrome a 3, thereby forming a tyrosine
radical, and this is known as the P compound (26). Electron transfer from
cytochrome c along with two protons from the mitochondrial matrix allows
tyrosine 244 to revert back to its phenolic state with the release of H2O. A final
electron transfer from cytochrome c and acquisition of another proton yields an
oxidized cytochrome a3-CuB complex completing the electron transfer cycle (26).
Complex IV contributes to the electrochemical proton gradient by consuming four
mitochondrial matrix hydrogen ions during the reduction of O 2 to H2O thereby
depleting matrix hydrogen ions and by translocating 4 hydrogen ions into the
inner membrane space (26). The D channel extends from the mitochondrial
matrix to the cytochrome a3-CuB center and connects with the exit channel.
Together the D-channel and exit channel function to pump hydrogen ions from
the matrix into the inner membrane space (25).

ATP synthase

ATP synthase uses the electrochemical gradient created by complex I, III
and IV to synthesize ATP from ADP and phosphate (Pi). ATP synthase is
composed of two functional subunits, F0 and F1, where F0 is a transmembrane
protein and F1 is a peripheral membrane protein (27). The F1 subunit is
responsible for binding ADP, Pi and the formation of ATP and is composed of
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three alpha and beta subunits along with a gamma, delta and epsilon subunit
(27). The F0 subunit binds hydrogen ions and is composed of three
transmembrane subunits, a, b and c (27). Hydrogen ions enter a hydrophilic
channel between the a subunit and the c-ring where they bind to the c-subunit of
the F1 subunit causing the c-subunit to rotate until it reaches another hydrophilic
channel where it releases the hydrogen ion (28). The free energy released by
hydrogen ion translocation drives the interconversion of the beta subunit of F0
from a L (loose) state to a T (tight) state and an O (open) state (28). ADP and Pi
bind to the beta subunit of F0 during the L state and the free energy provided by
hydrogen ion transport causes conformational changes that covert the L state to
a T state that catalyzes the formation of ATP (28). In addition, the other beta
subunits are converted from a T state to an O state and from an O state to a L
state, allowing ATP to dissociate from the O state (27).
Overall, the ETC of mitochondria provides energy to the cell in the form of
ATP by coupling electron transport to oxidative phosphorylation by creating a
proton gradient. Mitochondria are essential for cell survival by providing ATP.
However, they also play a role in cell death via apoptosis.

Mitochondrial mediated apoptosis

Intrinsic apoptosis is mediated by mitochondria following an apoptotic
stimuli such as DNA damage or endoplasmic reticulum (ER) stress, which
activate B cell lymphoma-2 (BCL-2) homology 3 (BH3)-only proteins, such as
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BCL-2-associated X protein (BAX) (29) and BCL-2 antagonist or killer (BAK) (30).
Upon activation BAX and BAK undergo oligomerization and target to
mitochondria, where they induce mitochondrial outer membrane permeabilization
(MOMP) (31). MOMP leads to the release of mitochondrial proteins such as
cytochrome c, HtrA2 apoptosis inducing factor and SMAC (30). Cytochrome c
binds to apoptotic-activating factor 1 (APAF1) leading to formation of the
apoptosome, which recruits and activates caspase 9. Caspase 9 cleaves and
activates caspase 3 and 7 leading to apoptosis. SMAC and HtrA2 serve to
counteract the caspase inhibitory functions of X-linked inhibitor of apoptosis
protein (XIAP) allowing for downstream activation of caspases and initiation of
apoptosis (31). Regulation of mitochondrial mediated apoptosis during MI is
essential in salvaging viable myocardium, thereby limiting cardiac injury (14).

Role of Mitochondria in Myocardial Infarction

The activation of apoptosis by mitochondria during MI results in
cardiomyocyte cell death and contributes to cardiac injury (14). Mitochondria also
produce ROS during MI, damaging protein, lipids, and DNA leading to cardiac
injury. Numerous studies have highlighted a role for mitochondrial dysfunction in
CVD including increased mitochondrial DNA damage (32) and decreased
mitochondrial respiration (33). Additionally, MI is associated with mitochondrial
dysfunction including increased mitochondrial DNA damage (34), decreased
mitochondrial encoded gene transcripts and decreased complex I, III, and IV
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activity (34). Mitochondrial induced ROS generation is a hallmark of ischemic
cardiac injury and believed to be the major contributor of cardiac injury. The
electron transfer reactions within the ETC can result in the direct transfer of
electrons to molecular O2 producing superoxide (O2.-) (Fig. 2) that is dismutated
to hydrogen peroxide (H2O2) by mitochondrial superoxide dismutase (MnSOD).
Mitochondria therefore produce a basal amount of ROS during respiration.
However, during MI there is an increase in ROS generation (18). The lack of
oxygen during ischemic injury results in back up of electron flow through the ETC
and reoxygenation following reperfusion results in a burst of ROS. Mitochondria
contain several enzymes that can produce ROS, including 2-oxoglutarate
dehydrogenase (35, 36) and pyruvate dehydrogenase (PDH) (37). However,
complex I, II and III contribute the majority of ROS (38). Studies limiting ROS
production by mitochondria during ischemic injury either by overexpression of
antioxidants such as SOD (39) or direct modulation of complex I activity (40),
provide cardiac protection highlighting the importance of regulating ROS
production during ischemic injury. While mitochondria contribute to cardiac injury
during MI via apoptosis and ROS generation; mitochondria can also provide
protection against MI (17).
Ischemic preconditioning (IPC) was first demonstrated by Murry et al. in
1986 in which short periods of ischemia could provide protection against a
subsequent prolonged ischemic insult (41) and mitochondria play a prominent
role in IPC. During IPC mitochondria can produce ROS that serve to activate
protective signaling pathways such as nuclear factor erythroid 2-related factor 2
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Figure 2. Superoxide generated by mitochondria.

.-

O2
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O2

Figure 2. Superoxide generated by mitochondria. Complex I, II, and III
generate superoxide (O2.-) during respiration due to electron slippage. During
ischemia reperfusion conditions the rate of superoxide generated by complex I, II
and III is increased.
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(Nrf2), hypoxia inducible factor 1 alpha (HIF-1α) (42), nuclear factor-kappa B (NFκB) (42), and adenine monophosphate kinase (AMPK) (43) that serve to protect
myocardium against ischemic injury, highlighting a protective cell signaling role
for mitochondrial ROS. Opening of the mitochondrial potassium-ATP (mitoKATP)
channel and mitochondrial permeability transition pore (MPT) during IPC is also
associated with cardioprotective effects (43). Alterations in mitochondrial
respiration and ATP synthesis via mitochondrial uncoupling (44, 45), posttranslational modifications on mitochondrial proteins (complex I and adenine
nucleotide translocase-1 (ANT-1)) (40, 46), and changes in mitochondrial
membrane potential (47) are also associated with IPC cardiac protection. Direct
activation of these mitochondrial protective signaling pathways has also been
shown to be cardioprotective against ischemic injury showing that mitochondria
are critical mediators of cardioprotective signaling (42, 48).

Role of Mitochondria in Aging

Aging is associated with a change in redox status of mitochondria. This
change is related to an increase in ROS generation, where the antioxidant
capacity within mitochondria becomes less efficient (42). Mitochondrial ROS
generation is associated with mitochondrial DNA damage, mitochondrial protein
damage and mitochondrial dysfunction in aging. Mitochondrial damage and
dysfunction can trigger apoptosis leading to increased cell death during aging.
Age is a significant risk factor for MI and is also associated with cardiac
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dysfunction. ROS induced mitochondrial damage is seen both in aging and
ischemic injury suggesting a similar mechanism of mitochondria induced cardiac
dysfunction (42). Importantly, the mitochondrial protective signaling pathways
against MI also serve to protect against aging induced mitochondrial dysfunction
such as MPT opening, AMPK and HIF-1 alpha (42).

Nitrite

History and Sources
The anion nitrite (NO2-) was considered an inert end product of NO
oxidation and was used as an indirect measurement of nitric oxide synthase
(NOS) activity. However, numerous studies have demonstrated that nitrite can
serve as a signaling molecule and an endogenous reservoir of NO (49). The two
main sources for NO2- are the oxidation of NO and the reduction of dietary
sources of nitrate (NO3-), found in green leafy vegetables and meat, via
commensal bacteria in the mouth. Initial data suggested the reduction of nitrite to
NO under conditions of low pH and hypoxia was responsible for the resulting
biological signaling actions (50). However, more recent data demonstrates that
nitrite can mediate effects independent of its conversion to NO (40, 51).

Nitric Oxide
Early studies of nitrite focused on its bioactivation to NO, as NO signaling
has been shown necessary for normal cardiovascular health (52). Nitric oxide
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was first discovered in the late 18th century and for 200 years was widely
considered to be a toxic gas. In the 1980s, it was discovered that NO was
generated in mammals by nitric oxide synthases (53). There are three forms of
nitric oxide synthases (NOSs): the endothelial nitric oxide synthase (eNOS), the
neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase
(iNOS). NOSs are composed of homodimers (53). Each dimer contains a
reductase and oxygenase domain that catalyzes a five electron transfer reaction
and results in the conversion of L-arginine and molecular oxygen to L-citrulline
with the concomitant production of NO (53). eNOS is found within the vascular
endothelium, and the production of NO from eNOS is important for
cardiovascular health, as NO maintains vascular tone and endothelial integrity
(54).
NO can mediate biological signaling through three different pathways due
to its free radical nature and high reactivity with transition metals and other free
radicals. Direct interaction with ferrous heme proteins, direct diffusion-limited
reactions with radicals, lipid peroxides and thiol radicals to form S-nitrosothiols
and oxidative reactions with oxygen or ROS; represent the three distinct
pathways in which NO can exert biological effects (55). Nitric oxide reactions
occur with heme proteins and other radicals at low concentrations (picomolar to
nanomolar) of NO due to the high affinity of NO for these compounds, while
higher concentrations of NO and ROS are needed to form reactive nitrogen
species such as nitrosonium (NO+), nitrogen dioxide (NO2) or dinitrogen trioxide
(N2O3).
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Nitric oxide’s affinity for ferrous heme molecules leads to formation of an
iron-nitrosyl complex and such binding activates soluble guanylate cyclase (sGC)
(56). sGC activation leads to generation of the second messenger cyclic
guanosine 3’-5’-monophosphate (cGMP), which activates protein kinase G (PKG)
leading to relaxation of vascular smooth muscle and vasodilation within blood
vessels (54). The NO-sGC-cGMP signaling cascade is the classical pathway by
which NO facilitates regulation of vasomotor tone within the cardiovascular
system (56). However, NO can also mediate a wide variety of effects including
angiogenesis

(56),

mitochondrial

biogenesis

(56)

and

modulation

of

mitochondrial function (57). Conditions of increased oxidative stress, such as
inflammation, MI, and aging, can impact NO signaling by decreasing NO
availability and desensitizing sGC to NO (42). Increased O2.- production during
oxidative stress can react rapidly with NO to form peroxynitrite (ONOO -) thereby
reducing NO concentrations (55).
Oxidative stress can also oxidize eNOS via glutathionylation (58) and
reduce tetrahydrobiopterin (BH4) (58), a redox sensitive co-factor for eNOS. The
loss of BH4 leads to uncoupling of eNOS, allowing electrons from NADPH to be
passed to oxygen resulting in superoxide formation instead of NO (58). The
ferrous heme of sGC can be oxidized to ferric heme resulting in sGC that is
resistant to NO, thereby decreasing NO signaling (58). Loss of nitric oxide
signaling and subsequent endothelial dysfunction is a hallmark of aging (42) and
loss of nitric oxide in animals models of MI via NOS inhibition (52) or NOS
genetic knockout (52) results in worsening cardiac injury. These studies highlight

20

a protective role of NO in aging and MI and the protection afforded by NO
appears to be in part mediated by mitochondria.
Activation of the NO-sGC-cGMP pathway leads to opening of the mitoKATP
channel leading to reduced calcium overload in mitochondria (59). Inhibition of
MPT opening, thereby decreasing cytochrome c release and apoptosis (60) has
also been attributed to nitric oxide. NO has also been shown to inhibit
mitochondrial complex I (51), thereby decreasing ROS production and allowing
diffusion of oxygen to ischemic tissue providing protection against ischemic
injury. The hypoxic and acidic conditions associated with ischemic injury renders
NOSs uncoupled leading to increased ROS and diminished NO production
thereby limiting the therapeutic potential of NO against MI (52). However, nitrite
represents an endogenous storage pool of NO (49).

Nitrite Reduction
Nitrite can be reduced to nitric oxide under conditions of low pH, as was
first noted by Furchgott (50) as acidified sodium nitrite solutions were able to
mediate transient relaxation of rabbit aorta very similar to NO gas. Nitrite can be
converted to NO in the acidic conditions such as the gastric lumen via nonenzymatic reaction. Nitrite is protonated (HNO2) and decomposes to N2O3, giving
rise to NO and NO2 (61). Nitrite can also be reduced to NO under hypoxic
conditions by deoxygenated hemoglobin, where nitrite reacts with the ferrous
hemoglobin and a proton to produce NO and methemoglobin (62). This reduction
is highly dependent on low oxygen and low pH conditions, which arise during MI.
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Nitrite reduction to NO can be catalyzed by several enzymes including:
myoglobin (63), neuroglobin (64), cytochrome c (65), complex IV (66), eNOS (67)
and xanthine oxidoreductase (68). While the exact mechanisms of nitrite
reduction for all these enzymes is unknown, the prevailing conditions of low pH
and hypoxia increase the reaction rate of nitrite reduction. The reduction of nitrite
to NO, allows nitrite to mediate a variety of effects including: NO-sGC-cGMP
signaling (69), metabolic signaling (70), vasodilation (62) and most importantly
protection against ischemia reperfusion injury (40, 71-73).

Nitrite and Myocardial Infarction
Nitrite was first shown to be cardioprotective in a Langendorff model of MI
by decreasing infarct size (74). Abolishing NO signaling negates the protective
effect of nitrite suggesting that reduction of nitrite to NO is required for
cardioprotection as deletion of myoglobin, a nitrite reductase, in mice resulted in
blunting of nitrite cardioprotection (75). This reinforces that nitrite reduction to NO
is necessary for nitrite-mediated cardioprotection. Nitrite has also been shown to
be protective in other models of ischemic injury including liver (76), brain (77),
and hindlimb ischemia (78) with all of these studies indicating the reliance on
nitrite reduction to NO. Nitrite also appears to be involved in the protection
conferred by IPC as blood and tissue nitrite concentrations increase following
IPC (79). Together these studies demonstrate that nitrite given during the acute
phase of ischemia mediates protection against ischemic injury with mitochondria
appearing to mediate this protection.
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Nitrite and Mitochondria
Mitochondria contain several components that can serve to reduce nitrite
to NO including complex III (80), complex IV (66), and cytochrome c (65). Nitrite
can also serve to modulate mitochondrial function either directly via posttranslational modifications on complex I (40) and complex IV (81) or indirectly via
mitochondrial biogenesis (82) and mitochondrial fusion (83, 84). Complex I
induced ROS generation during the reperfusion phase of IR injury is a critical
component of IR tissue injury and inhibition of complex I (85) has shown to be
protective. Complex I activity has been shown to decrease with nitrite treatment
during ischemia (73) and this decrease in complex I activity resulted in
suppressed mitochondrial respiration ultimately leading to protection against IR
injury (73) (Fig. 3).
A recent study by Chouchani et al. followed up on this nitrite-mediated
decrease in complex I, and demonstrated that S-nitrosylation on cysteine 39 of
the ND3 subunit was responsible for the decreased complex I activity (40).
During ischemia when levels of NADH and oxygen are low, complex I activity is
decreased and the ND3 subunit undergoes a conformational change exposing
cysteine 39 (40). Nitrite and an exogenous NO donor given prior to ischemia are
able to S-nitrosylate cysteine 39 and this modification decreases complex I
activity, thereby attenuating ROS generated by complex I during reperfusion (40).
Importantly, the S-nitrosylation on cysteine 39 is a transient, reversible
modification allowing for complex I enzymatic activity to return following
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Figure 3. Mitochondrial targets of nitric oxide and nitrite.
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Figure. 3. Mitochondrial targets of nitric oxide and nitrite. During normoxic
conditions nitric oxide (NO) mediates cyclic GMP (cGMP) signaling and can
inhibit complex IV, reducing oxygen consumption by mitochondria. Under low
oxygen concentration nitrite (NO2-) can be converted to NO by deoxygenated
myoglobin (Mb), xanthine oxidoreductase (XO), complex III, and complex IV
(ETC) allowing for complex IV inhibition. Nitrite can directly inhibit complex I via
S-nitrosylation during ischemia resulting in suppressed oxidative stress leading to
protection.
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ischemia. Overall, the S-nitrosylation on cysteine 39 within the ND3 subunit of
complex I serves to decrease complex I generated ROS and preserve complex I
activity.
Nitrite via conversion to NO has been shown to compete with oxygen for
binding to the cytochrome a3 and CuB binuclear complex and this inhibits
complex IV activity leading to suppression of oxygen consumption (81). NO
inhibition of complex IV is reversible and this inhibition is thought to be a
protective mechanism by preserving oxygen levels in hypoxic tissue.
Other mitochondrial mechanisms of protection with nitrite include inhibition
of MPT opening (73), mitochondrial fusion (84), and AMPK activation (82). The
opening of the MPT allows the release of cytochrome c into the cytosol inducing
activation of the intrinsic pathway of apoptosis and nitrite is associated with
decreased apoptosis in IR injury. The exact mechanism of nitrite reducing MPT
opening and cytochrome c release remains unknown, as this may occur through
reduction in ROS (40), direct inhibition of cytochrome c release via nitrosylation
(86) or modulation of MPT protein components (87). Nitrite activation of PKA
mediates phosphorylation of dynamin related protein 1 (Drp1) leading to
inactivation and an increase in mitochondrial fusion (84). Attenuation of
increased Drp1 protein levels following MI is associated with cardioprotection
(88), suggesting that nitrite plays a role in mitochondrial dynamics. Nitrite induced
mitochondrial fusion also leads to activation of AMPK leading to mitochondrial
biogenesis (84) and AMPK activation is known to be cardioprotective (89).
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Overall, mitochondria appear to play a prominent role in protective effects of
nitrite.
The numerous studies highlighting the cardioprotective effects of nitrite
lead to two clinical trials to determine whether nitrite supplementation during
acute MI in humans was protective (90, 91). Both clinical trials cited no protective
effect of nitrite in acute MI, suggesting that nitrite-mediated cardioprotection is
not applicable in humans. While the hypoxic environment allows for nitrite
conversion to NO, it also allows the formation of nitrogen species such as
nitrogen dioxide and NO+. Additionally, NO can react with superoxide to form
peroxynitrite. Nitrogen dioxide and peroxynitrite can react with thiols and
tyrosines on proteins (92), altering protein function. Nitrogen dioxide and the
nitrosonium ion can react with alkenes resulting in the formation of nitro-fatty
acids (93). In this regard the cardioprotection afforded by nitrite may be
influenced by the surrounding environment such as proteins or alkenes that can
be post-translationally modified by secondary nitrogen species arising from
nitrite.

Conjugated Linoleic Acid

Sources and Structure
Conjugated linoleic acid or cLA is an 18:2 unsaturated fatty acid and is an
isomer of linoleic acid (Fig. 4). There are 28 different isomers of cLA with the cis-
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Figure 4. Cis-9 trans-11 isomer of conjugated linoleic acid

-O
O
Figure 4. Cis-9 trans-11 isomer of conjugated linoleic acid. Conjugated
linoleic acid is an 18:2 fatty acid with the cis-9 trans-11 isomer containing two
double bonds at positions 9 and 11.
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9 trans-11 and trans-10 cis-12 isomers comprising the majority of the cLA (94).
cLA is produced in ruminant animals by two pathways: 1. bacteria within the
stomach that isomerizes linoleic acid to cLA and 2. delta-9-desaturase
conversion of vaccenic acid (trans-11 18:1 fatty acid) to cLA. The delta-9desaturase pathway of cLA represents the majority source of cLA in cattle (95).
cLA is found within a variety of foods including beef, pork, lamb, chicken, milk,
butter, cheese, and vegetable oils (96). The total amount of cLA in beef is
approximately 1% of fat and cLA content can increase by supplementing forage
and oils to cattle (97). The majority of total cLA within dietary food products is
composed of the cis-9 trans-11 isomer of cLA representing approximately 90% of
total cLA. The estimate of dietary intake of cLA within adults in the United States
is 0.2g/day (98), with dietary habits such as higher intake of ruminant fat
influencing individual dietary intake of cLA. cLA levels can also be increased by
cLA supplementation, as cLA is commercially sold as a weight loss supplement
that is unregulated by the Food and Drug Administration (FDA) (99). The FDA
also excludes cLA from nutrition labeling regulations requiring levels of trans fats
in food to be disclosed, as cLA is labeled as a natural trans-fat (99). As trans fats
from hydrogenated oil are linked to increased cardiovascular risk factors, efforts
have been made to understand the role of cLA in cardiovascular health and
disease.

Biological Role of cLA
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Conjugated linoleic acid has been evaluated in numerous epidemiological
studies assessing the risk of cardiovascular disease or MI (100, 101). cLA
displayed neither a positive nor a negative correlation for development of MI or
cardiovascular disease, with exception of one study in which adipose cis-9 trans11 cLA was associated with lower risk of MI (102). cLA can act as a peroxisome
proliferator-activated receptors (PPARs) agonist and PPAR activation leads to
gene transcription involved in lipid metabolism, insulin signaling and inflammation
(103). The effect of cLA on weight loss in animal models has translated over to
humans as cLA is commercially sold as a weight loss supplement. However, the
FDA

does not

regulate

cLA.

The

target

patient

population for cLA

supplementation is obese individuals setting to lose weight.
In clinical trials of obese individuals cLA had no effect on lipid profiles and
the cis-9 trans-11 isomer of cLA increased 8-iso-prostaglandin F2α (8-isoPGF2α) levels in urine (104). 8-iso-PGF2α is a marker of lipid peroxidation
suggesting that cLA increases lipid peroxidation in obese individuals. cLA has
been shown to increase ROS production in macrophages (105) and promote
oxidative stress in cardiac tissue of male Wistar rats (106), potentially explaining
the increased 8-iso-PGF2α in obese individuals. The cis-9 trans-11 isomer of cLA
has been shown to uncouple eNOS and increase NADPH oxidase 2 (Nox2)
protein expression in endothelial cells and murine cardiac tissue (107). This
uncoupling of eNOS and increased Nox2 expression could lead to an increase in
oxidative stress. In contrast to these results, cLA has also been shown to be
beneficial. Healthy male individuals given 3 doses of cis-9 trans-11 cLA displayed
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a significantly reduced total cholesterol to high density lipoprotein cholesterol
(TC:HDL-C) ratio (108). The most significant beneficial effect of cLA in relation to
cardiovascular disease is the reduction in atherosclerosis and total cholesterol
(109-111). The cis-9 trans-11 isomer of cLA decreased atherosclerotic lesions in
the aorta (109), reduced total cholesterol (110) and cholesterol accumulation
within the aorta (111).
Two potential pathways for cLA’s mechanism of action have been
described: 1. activation of PPARs and 2. inhibition of cyclooxygenase (COX),
which is responsible for production of prostaglandins and thromboxane
necessary for inflammation and vascularization (94). The activation of PPARα by
cLA (112) leads to gene transcription of several genes involved in beta oxidation
and increased mitochondrial biogenesis (113). The activation of PPARα links the
ability of cLA to modulate lipid metabolism but PPARα knockout mice displayed
similar lipid metabolism as wild type mice supplied with cLA (114), suggesting
cLA mediates changes in lipid metabolism independent of PPARα (114).
Mitochondria play a central role in lipid metabolism as beta oxidation of
fatty acids occurs within mitochondria and cLA has been shown to mediate
changes at the level of mitochondria. cLA has been shown to inhibit the beta
oxidation of other fatty acids within the liver (115), increase activity of carnitine
palmitoyltransferase I (CPTI) (116) and increase activity of the mitochondrial
citrate carrier (116). These results suggest cLA is able to directly modulate
mitochondrial function; however the impact of cLA on cardiac mitochondrial
function is unknown.
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The literature on cLA suggests a wide array of biological effects including
beneficial, detrimental or no effect (101). This can be explained by dose and
duration of cLA administration. Most animal studies using cLA give super
physiological doses of cLA and the duration of cLA ranges from days to weeks
(101). The composition of the cLA dose is important to consider as well, and the
majority of studies have used an isomeric mixture of cLA composed of both cis-9
trans-11 and trans-10 cis-12. This is an important characteristic of study design
as these isomers can have differing effects on study end points (101). Due to the
high abundance of the cis-9 trans-11 isomer of cLA within the diet it is important
to study the isomeric specific effects. The cis-9 trans-11 isomer of cLA decreased
cardiac function in aged mice and co-administration of nitrite reversed this
cardiac dysfunction (107). The interaction of cLA and nitrite brings up an
overlooked mechanism of action of cLA; the nitration of cLA. Due to the
conjugated double bond nature of cLA, the cis-9 trans-11 isomer is the preferred
endogenous substrate of fatty acid nitration (117).

Nitrated Fatty Acids

Mechanisms of Formation
The formation of nitrated fatty acids is induced by NO derived species
reacting via multiple mechanisms, ultimately resulting in the addition of nitrogen
dioxide to a double bond. Peroxynitrite, oxidation of nitrite, protonation of nitrite,
and aerobic reactions of NO (93) are all mechanisms that can mediate nitration
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of fatty acids; thereby depicting a complex interaction between NO, NO derived
oxides of nitrogen, peroxynitrite, and oxygen derived inflammatory mediators (ex.
superoxide) leading to nitrated fatty acids. Fatty acids such as linoleic and oleic
acid are targets of nitration due to their high abundance and double bond
structure lending to nitrogen dioxide addition via either homolytic or hetrolytic
reactions (93). The formation of nitrated fatty acids is influenced by
microenvironment including:

aqueous vs hydrophobic environment, flux of

nitrating and oxidizing species, antioxidants, and fatty acid beta-oxidation rates
(118). Nitrated fatty acids exist in an equilibrium between the nitroalkene and
nitrohydroxy form as nitro-fatty acids react under hydroxide anions within water
(93). Nitroalkenes are stable in free or esterified forms under hydrophobic
conditions such as lipid membranes or lipoproteins and once released to
aqueous environments can either release NO, bind and activate PPARs, or posttranslational modify proteins (118).

Biological Role of Nitrated Fatty Acids
Nitroalkenes decay in aqueous solutions leading to the release of NO;
however, under physiologically conditions the release of NO by nitrated fatty
acids is less than one percent (93). Nitroalkenes have been shown to activate
PPAR gamma leading to decreased insulin and glucose levels in leptin deficient
mice (119) and elevated nitrated fatty acids are found in the plasma of
postprandial and hyperlipidemic humans (120). The activation of PPAR gamma
by nitro-fatty acids was similar to the diabetic drug rosiglitazone without the
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increased adipogenesis suggesting a unique mechanism of action of PPAR
gamma by nitro-fatty acids (121). A more important and diverse role of nitrated
fatty acids is in inflammation.
Due to the electrophilic nature of nitrated fatty acids, they can react with
protein thiols and histidine residues, thereby modulating cell signaling (93).
Kelch-like ECH-associating protein 1 (KEAP1) is a cytoplasmic repressor protein
of Nrf2 which holds Nrf2 in the cytoplasm in an inactive state. KEAP1 contains a
reactive cysteine that undergoes electrophilic modification by nitrated fatty acids
(122) allowing Nrf2 to translocate to the nucleus and upregulate the transcription
of phase II antioxidant enzymes. Heme-oxygenase-1 (HO-1) is one of these
phase II antioxidant enzymes and nitrofatty acids have been shown to increase
HO-1 protein expression (123). Nitrated fatty acids can also nitroalkylate p65, a
component of the NF-κB inflammatory signaling pathway, thereby inhibiting p65
DNA binding (124) and decreasing pro-inflammatory cytokine gene expression.
Due to the increase in nitrative and oxidative stress associated with MI,
the formation of nitrated fatty acids increases following ischemia reperfusion
injury (125). The exogenous administration of a nitrated oleic acid prior to
ischemia reperfusion injury reduced infarct size (47), showing endogenous
generation or exogenous administration of nitrated fatty acids is cardioprotective.
Research into the mechanisms by which nitroalkenes mediate cardioprotection
highlighted a mitochondrial mechanism as nitroalkenes promote mitochondrial
uncoupling (47) and nitroalkylation of ANT-1 (46). Importantly, mitochondrial
targeted nitroalkenes are more protective than non-mitochondrial nitroalkenes
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(126). Recent evidence has shown that cLA is the preferred endogenous
substrate for fatty acid nitration, generating nitro-cLA (117, 127) and a
combination of cLA and nitrite is protective against cardiac injury (88). Due to the
highly dependent role of mitochondria on nitro-fatty acid cardioprotection, it
remains unknown if precursors to fatty acid nitration (cLA and nitrite) modulate
mitochondrial function under baseline and cardiac injury settings.

Hypothesis and Research Strategy
It is clear that cLA, nitrite and mitochondria play important roles in
cardiovascular health and disease; therefore it is important to investigate the
effect of cLA and nitrite consumption on mitochondrial function. To evaluate the
impact of cLA and nitrite on cardiac mitochondrial function the following
hypothesis was proposed: Co-treatment of cLA and nitrite protects against
cardiac injury and age related cardiac dysfunction via beneficially altering
mitochondrial function.
In this study, cardiac mitochondrial function was examined under baseline
and cardiac injury conditions following cLA, nitrite and the combination treatment
of cLA and nitrite. We first examined the impact on cardiac mitochondria
following a ten day treatment with cLA, nitrite and co-treatment with cLA and
nitrite under baseline conditions. This was followed up by examining the impact
of MI and aging on cardiac mitochondrial function and how treatment with cLA,
nitrite and co-treatment with cLA and nitrite mediated changes in cardiac
mitochondrial function following MI and aging.
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Our results demonstrate that co-treatment with cLA and nitrite decreases
mitochondrial state 3 respiration and complex III activity. In addition, we found
that MI increases mitochondrial state 3 respiration, complex III activity, and
hydrogen peroxide generation. However, the co-treatment of cLA and nitrite was
able to attenuate these changes, potentially contributing to cardioprotection.
These results reveal that in vivo supplementation of cLA and nitrite is able to
modulate mitochondrial function and provides an explanation for cLA and nitrite
cardioprotection.
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CHAPTER II
MATERIAL AND METHODS

Experimental Procedures
Animals
C57BL/6J mice were obtained from Jackson Laboratory and all animal
studies were approved by the University of Louisville Institutional Animal Care
and Use Committee. Mice were fed standard chow and water ad libitum.

Experimental Design
Chapter III
C57BL/6J mice divided into four groups: control, cLA, nitrite, and
cLA/ nitrite. cLA was given via osmotic mini-pump (20mg/kg/d) and sodium nitrite
(50ppm) was supplemented in drinking water for 10 days.
Chapter IV
C57BL/6J mice were divided into eight groups: control, cLA, nitrite,
cLA/nitrite, MI- control, MI- cLA, MI- nitrite, MI- cLA/nitrite. cLA was given via
osmotic mini-pump (20mg/kg/d for non-MI and 10mg/kg/d for MI) and sodium
nitrite (50ppm) was supplemented in drinking water for 3 days prior to MI and
continued for 10 days after MI.
Chapter V
36

C57BL/6J mice were aged to 10 or 33 month prior to treatment.
Mice were divided into four groups: control, cLA, nitrite, and cLA/ nitrite. cLA was
given via osmotic mini-pump (20mg/kg/d) and sodium nitrite (50ppm) was
supplemented in drinking water for 6 weeks.

Blood Glucose Measurements
Mice were fasted overnight prior to blood glucose measurements from tail
blood using the TRUEresult (NIPRO Diagnostics) blood glucose monitor.
Measurements were taken prior and following treatment for control, cLA, nitrite
and cLA/nitrite.

Mouse Model of Myocardial Infarction
Male C57BL/6J mice, 10- to 12-wks old, were anesthetized with
isoflurane, intubated and ventilated with CWE advanced ventilator (Webster,TX).
Body temperature was maintained with an Indus Temperature feedback/surgical
table and ECG system. Aseptic procedure was used for preparation of the
surgical site through scrubbing with a 0.8% chlorhexidine solution. A left
thoracotomy was performed via the fourth intercostal space and the lungs
retracted to expose the heart. After opening the pericardium, the left anterior
descending (LAD) coronary artery was ligated with an 8–0 silk suture near its
origin between the pulmonary outflow tract and the edge of the atrium. Ligation
was deemed successful when the anterior wall of the left ventricle (LV) became
pale in color. The lungs were inflated by increasing positive end-expiratory
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pressure, and the thoracotomy side was closed in layers. The lungs were reexpanded, and the chest was closed. The animals were removed from the
ventilator and allowed to recover on a heating pad. Mice were checked daily for
signs of pain or distress and buprenorphine at 0.05mg/kg SQ is given before and
every 12h for 48 hours.

Heart Mitochondria Isolation
Hearts were excised and placed immediately in ice cold isolation media 1
(250mM sucrose, 0.5mM Na2EDTA, and 10mM Tris, pH 7.4). Hearts were
minced, washed 3 times and homogenized at 40 RPM using the GKHHomogenizer (Glas-Col). Heart homogenate was centrifuged at 1000 x g for 3
minutes at 4°C and supernatant was filtered through gauze sponge into a new
tube followed by centrifugation at 10,000 x g for 10 minutes. The mitochondrial
pellet was washed using isolation media 2 (250mM sucrose, 0.5mM Na 2EDTA,
10mM Tris, and 1g/L BSA, pH 7.4) and centrifuged at 10,000 x g for 10 minutes.
The mitochondrial pellet was washed again with isolation media 2 and
centrifuged at 10,000 x g for 10 minutes. Following centrifugation the
mitochondrial pellet was dissolved in respiration media (0.5mM EGTA, 3mM
MgCl2, 60mM K-lactobionate, 20mM taurine, 10mM KH2PO4, 20mM HEPES,
110mM Sucrose, and 1g/L BSA). Heart mitochondria concentration was
determined using the Bradford Protein Assay and was used immediately for
respiration or stored at -80°C for complex activity or western blot.
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Respiration
Mitochondria (0.025mg/ml) was added to closed Oxygraph-2k (Oroboros
Instruments) chambers containing 2ml of respiration buffer (0.5mM EGTA, 3mM
MgCl2, 60mM K-lactobionate, 20mM taurine, 10mM KH2PO4, 20mM HEPES,
110mM Sucrose, and 1g/L BSA). LEAK (proton leak) respiration was measured
following addition of 10mM glutamate and 2mM malate, followed by addition of
1mM ADP for measurement of State 3 respiration. Cytochrome c (2.5μM) was
added following induction of State 3 respiration as a control to ensure maximal
respiration in State 3 and evaluate integrity of the outer mitochondrial membrane.
Oligomycin A (2.5μM) was then added to induce State 4 respiration, followed by
addition of 3.5μM carbonyl cyanide p-trifluoro-methoxyphenyl hydrazone (FCCP)
to obtain maximum mitochondrial respiration in the non-coupled state of electron
transfer system capacity. Upon depletion of oxygen 0.5μM antimycin A, a
complex III inhibitor, was added to the chamber followed by re-oxygenation to
measure residual oxygen consumption due to oxidative side reactions. Figure 5
shows representative Oxygraph-2k graph following respiration protocol.

Complex I Activity Assay
Complex I activity assay was adapted from previously described method
(128) with slight modification. Briefly, mitochondria were diluted to concentration
of 0.2 μg/μl and sonicated (QSonica) 4x for 5 seconds. 12μg of mitochondria was
added to reaction mixture (25mM potassium phosphate pH 7.4, 80μM NADH,
2mM KCN, 2μM antimycin A, 60μM decyclubiquinone, and 3 mg/mL BSA) in 1.5
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mL cuvette (Starna Cells) and change in absorbance was read at 340nm for 4
minutes using Synergy 2 (BioTek) spectrophotometer. Rotenone (4μM) was
added to reaction mixture to determine rotenone insensitive complex I activity
and subtracted from total activity to determine rotenone specific complex I
activity.

Complex II Activity Assay
Complex II activity assay was adapted from a previously described
method (129) with slight modification. Briefly, 5μg mitochondria was added to
reaction mixture (25mM potassium phosphate pH 7.4, 50μM decyclubiquinone,
80μM 2,6-Dichlorophenolindophenol sodium salt hydrate, 20mM succinate,
1mg/mL BSA and 300μM KCN) in1.5 mL cuvette (Starna Cells) and incubated for
10 minutes. Decyclubiquinone (50μM) was added to start reaction and change in
absorbance was monitored at 600nm for 4 minutes using Synergy 2 (BioTek)
spectrophotometer. Malonate (10mM) was added to reaction mixture to
determine malonate insensitive complex II activity and subtracted from total
activity to determine malonate specific complex II activity.

Complex III Activity Assay
Complex III activity assay was adapted from a previously described
method (129) with slight modification. Briefly, 5μg mitochondria was added to
reaction mixture (25mM potassium phosphate pH 7.4, 100μM decyclubiquinol,
75μM cytochrome c, 500μM KCN, and 100μM Na2EDTA) in 1.5mL cuvette and
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change in absorbance was read at 550nm for 4 minutes using Synergy 2
(BioTek) spectrophotometer. Antimycin A (10 μg/mL) was added to reaction
mixture to determine antimycin A insensitive activity and subtracted from total
activity to determine antimycin A specific complex III activity.

Complex IV Activity Assay
Complex IV activity assay was adapted from a previously described
method (129) with slight modification. Briefly, 5μg mitochondria was added to
reaction mixture (50mM potassium phosphate pH 7.4, and 30μM reduced
cytochrome c) in 1.5 mL cuvette (Starna Cells) and change in absorbance was
monitored at 550nm for 4 minutes using Synergy 2 (BioTek) spectrophotometer.
KCN (300μM) was added to reaction mixture to determine KCN insensitive
activity and subtracted from total activity to determine KCN specific complex IV
activity.

Western Blot Analysis
Heart tissue was snap frozen in liquid nitrogen and isolated mitochondria
were stored at -80°C until needed. Heart tissue was homogenized and protein
concentration determined using Bradford Protein Assay. Heart tissue or isolated
mitochondria samples were then sonicated 2x for 5 seconds and subjected to
SDS-PAGE method. MitoProfile® Total OXPHOS Rodent WB Antibody Cocktail
(1.5μg/mL) was purchased from ABCAM for NADH dehydrogenase ubiquinone 1
beta subcomplex 8 (NDUFB8), succinate dehydrogenase complex subunit B
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(SDHB),

ubiquinol-cytochrome

c

reductase

core

protein

II

(UQCRC2),

mitochondrially encoded cytochrome c oxidase 1 (MTCO1) and ATP synthase
subunit alpha (ATP5A).

H2O2 Assay
25μg of heart tissue supernatant was incubated in phosphate buffered
saline (PBS) pH 7.4, 49μM Amplex® UltraRed (Invitrogen), and 0.1U/mL
horseradish peroxidase (Simga) for 30 minutes. Absorbance was measured at
560nm and hydrogen peroxide concentration was calculated using hydrogen
peroxide standard curve.

Statistical Analysis
Data are presented as mean ± SEM. One way ANOVA with Bonferroni
post hoc test, two way ANOVA with Bonferroni post hoc test or unpaired
Student’s t-test were performed to determine significance using GraphPad Prism
6 software.
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CHAPTER III

COMBINATION TREATMENT WITH cLA AND NITRITE IN VIVO CHANGES
MITOCHONDRIAL FUNCTION
Chapter Overview
Nitrite and cLA are dietary components found in green leafy vegetables
and runimant meat respectively. cLA and nitrite are reported to have overall
benefits on cardiovascular health and studies have shown that either nitrite or
cLA can mediate changes in the activity of mitochondrial proteins and influence
mitochondrial metabolism. However, it is not known how a combination of both
cLA and nitrite impacts cardiac mitochondrial function. Cardiac mitochondria are
essential for maintaining normal cardiac function and the impact of dietary cLA
and nitrite on cardiac mitochondrial function may have a profound impact on
overall cardiac health and function. In this study we examined how cLA, nitrite
and a combination treatment of cLA and nitrite impacted cardiac mitochondrial
function and individual electron transport chain activity. This study is the first to
show that nitrite and cLA impact cardiac mitochondrial function in vivo.
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Introduction
Conjugated linoleic acid (cLA) is an 18:2 unsaturated fatty acid and an
isomer of linoleic acid. cLA is found within ruminant meat and dairy products with
the majority of dietary cLA, approximately 72-94%, composed of the cis-9 trans11 isomer. The dietary intake of cLA within the United States is approximately
0.2g/ day (98) and intake can increase as cLA is commercially sold as a weight
loss supplement. cLA plays a role in lipid metabolism and glucose homeostasis
(130) via activation of peroxisome proliferator activated receptor (PPAR)
activation (131). cLA can also directly mediate effects on mitochondria via
inhibition of fatty acid beta oxidation (115), increased activity of carnitine
palmitoyltransferase I activity

(116) and mitochondrial citrate carrier protein

(116). The role of the cis-9 trans-11 isomer of cLA on cardiac mitochondrial
function is unknown at this time.
Nitrite (NO2-) is a dietary constituent found within spinach and beet juice.
Dietary nitrite represents an endogenous reservoir of nitric oxide (NO), as nitrite
can be reduced to NO (62). NO plays an important role in cardiovascular health
due to its role in regulating vascular tone (62) via activation of soluble guanylyl
cyclase. More recent evidence suggests nitrite is cardioprotective via
mitochondrial dependent mechanisms including inhibition of mitochondrial pore
transition opening (73), mitochondrial fusion (84) and post-translational
modifications on complex I (40). Nitrite has also been shown to mediate changes
upstream of mitochondria including activation of protein kinase A (PKA) which
phosphorylates and inactivates dynamin related protein 1 (Drp1) leading to
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increased mitochondrial fusion (84). Nitrite also serves to activate adenine
monophosphate kinase (AMPK), (82) a metabolic sensor involved in modulating
metabolism. Due to the dietary nature of nitrite and its effects on mitochondria it
is important to assess how nitrite influences cardiac mitochondrial function.
Recent evidence from our lab reported that cLA induced cardiac
dysfunction in aged mice that was rescued with nitrite supplementation (107) and
combination treatment of cLA and nitrite is protective in a murine model of
myocardial infarction (MI) (88). Cardiac mitochondria play an essential role in
cardiac function and this study investigates how cLA and nitrite affects cardiac
mitochondrial function in vivo.
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Results
To test the hypothesis that co-treatment of cLA and nitrite would impact
mitochondrial function, mitochondrial respiration (as outlined in Fig. 5) was
assessed in cardiac mitochondria isolated from C57BL/6J mice treated with cLA,
nitrite and co-treatment. Weight measurements (Fig. 6A), demonstrated animals
remained healthy with given does of cLA and nitrite. Blood glucose (Fig. 6B) was
also monitored, as cLA (132) and nitrated fatty acids (93) can impact blood
glucose homeostasis, and was unaltered following all treatment groups.
Assessment of cardiac mitochondrial function demonstrated that state 3
respiration was significantly decreased following cLA and co-treatment with cLA
and nitrite (Fig. 7B), while LEAK respiration (Fig. 7A), state 4 respiration (Fig. 7C)
and ETS respiration (Fig. 7D) remained unchanged. The decrease in state 3
respiration was reflected in the respiratory control ratio (RCR) of cLA and cotreated mice (Fig. 7E) as the RCR was significantly decreased.
To determine if changes in mitochondrial respiration were due to changes
in electron transport chain enzymatic activity, complex I,II, III and IV enzymatic
activity assays were performed. Nitrite and the co-treatment of cLA and nitrite
increased complex I activity (Fig. 8A) compared to control, while the combination
treatment of cLA and nitrite decreased complex II (Fig. 8B) and III (Fig. 8C)
activity compared to control. Complex II activity was also decreased with cLA
treatment alone (Fig. 8B). Complex IV activity (Fig. 8D) showed no change with
any treatment group and the ten day treatment of cLA, nitrite and co-treatment
did not alter mitochondrial respiratory chain protein subunits (Fig. 9).
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Figure 5. Mitochondrial Respiration Protocol.

ETS
State 3

State 4
LEAK
ROX

Mito G + M

ADP

cytochrome c

FCCP

FCCP

Antimycin A

Oligomycin

Figure 5. Mitochondrial Respiration Protocol. Simultaneous changes in
oxygen concentration (black line, left y-axis) and oxygen flux per V (gray line,
right y-axis) is monitored over time following substrate addition (G + M; glutamate
and malate) where indicated. Mitochondrial LEAK (proton leak), State 3, State 4,
ETS (electron transfer system) and ROX (residual oxygen consumption)
respiration are obtained following substrate addition.
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Figure 6. Treatment with cLA, nitrite or combination does not alter animal weight and blood
glucose.
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Figure 6. Treatment with cLA, nitrite or in combination does not alter
animal weight and blood glucose. Weight (A) and blood glucose (B) were
monitored and remained unchanged following 10 day treatment with cLA, nitrite
and co-treatment with cLA and nitrite. (*p<0.05, control before vs control after,
Two way ANOVA, n=4 for all groups.)
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Figure 7. State 3 respiration decreases following cLA treatment.
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Figure 7. State 3 respiration decreases following cLA treatment. Ten day
cLA and cLA + nitrite treatment decreases State 3 respiration (B) and the RCR
(E) in cardiac mitochondria compared to control, while LEAK respiration (A),
State 4 respiration (C) and ETS respiration (D) remain unchanged (*p<0.05
compared to control, One way ANOVA. n=4 for control, cLA, and nitrite, n=8 for
cLA + nitrite).
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Figure 8. Co-treatment with cLA and nitrite decreases complex II and III activity, while
increasing complex I activity.
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Figure 8. Co-treatment with cLA and nitrite decreases complex II and III
activity, while increasing complex I activity. Complex I (A): cLA + nitrite and
nitrite increase complex I activity (*p<0.05 compared to control, #p<0.05
compared to cLA and cLA + nitrite, One way ANOVA, n=8 for control and cLA +
nitrite, n=7 for cLA and nitrite). Complex II (B): cLA + nitrite and cLA decrease
complex II activity (*p<0.05 compared to control, #p<0.05 compared to nitrite,
cLA + nitrite, One way ANOVA, n=4 for all groups). Complex III (C): cLA + nitrite
decreases complex III activity (*p<0.05 compared to control, #p<0.05 compared
to cLA and nitrite, unpaired student t-test, n=7 for control, n=6 for cLA and n=4
for nitrite and cLA + nitrite). Complex IV (D): Complex IV activity remains
unchanged in all treatment groups (n=4 for all groups).
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Figure 9. Mitochondrial respiratory chain protein subunit levels remain unchanged following
cLA, nitrite or combination treatment with cLA and nitrite.
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Figure 9. Mitochondrial respiratory chain protein subunit levels remain
unchanged following cLA, nitrite or combination treatment with cLA and
nitrite. Representative western blot of NDUFB8, SDHB, UQCRC2, MTCO1, and
ATP5A (A) protein expression from cardiac tissue of control, cLA, nitrite, and cLA
+ nitrite treated mice. Quantitated levels of NDUFB8 (B), SDHB (C), UQCRC2
(D), MTCO1 (E) and ATP5A (F) protein expression remain unchanged following
cLA, nitrite, and cLA + nitrite treatment compared to control (n=6 for all groups).
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Discussion
The ten day treatment with cLA decreases state 3 respiration (Fig. 7B)
and RCR (Fig. 7E) without changes in LEAK (Fig. 7A), state 4 (Fig. 7C) or ETS
respiration (Fig. 7D). cLA treatment did not alter mitochondrial respiratory chain
subunit proteins (Fig. 9), suggesting the changes in mitochondrial respiration
were not due to changes in mitochondrial complex protein levels. cLA has been
shown to alter mitochondrial substrate transporter activities (115, 116), inhibit
beta oxidation (115) and shift skeletal muscle metabolism from oxidative to
glycolytic metabolism (133). These results suggest the decrease in state 3
respiration by cLA is mediated by decreases in mitochondrial substrate
transporter activities or adenine nucleotide transport.
As nitrite has been associated with cardiac protection (72) and this
protection is in part mediated by mitochondria, the impact of nitrite on cardiac
mitochondrial function was assessed. Following a 10 day treatment of nitrite,
LEAK, state 4, state 3 and ETS respiration (Fig. 7) remained unchanged. Nitrite
supplementation has been shown to increase uncoupled mitochondrial
respiration (84), and the ETS respiration (Fig. 7D) following nitrite treatment was
increased albeit not significantly compared to control. These results show that
nitrite does not impact cardiac mitochondrial respiration under baseline
conditions. Interestingly, nitrite significantly increased complex I activity (Fig. 8A),
while complex II (Fig. 8B), III (Fig. 8C) and IV (Fig. 8D) activity remained
unchanged following nitrite treatment. The change in complex I activity was not
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mediated by increases in complex I protein as NDUFB8, a complex I protein
subunit, protein levels did not change (Fig. 9).
Nitrite has been shown to decrease complex I activity (40, 73), contrasting
the results seen following nitrite treatment (Fig. 8A). The differing results most
likely are due to the nitrite treatment on isolated mitochondria (73), ten minute
administration of an NO donor (40) and the decrease in complex I activity
occurred following cardiac injury. Complex I is prone to S-nitrosylation on multiple
subunits (134) which could alter activity suggesting nitrite plays a more dynamic
role in regulating complex I activity. Overall, these results demonstrate that nitrite
does not alter cardiac mitochondrial respiration under baseline conditions and
may play a more prominent role in regulating complex I activity.
As cLA and nitrite are both dietary constituents studying how these dietary
components impact cardiac mitochondria together is important. The cis-9 trans11 isomer of cLA is the preferential substrate for fatty acid nitration in vivo (117)
and nitrite can give rise to secondary nitrogen species that mediate nitration of
fatty acids.
The co-treatment with cLA and nitrite was able to decrease state 3
respiration (Fig. 7B) and the RCR (Fig. 7E), without altering LEAK (Fig. 7A), state
4 (Fig. 7C), or ETS (Fig. 7D) respiration. This result mimics the single treatment
of cLA on respiratory parameters (Fig. 7), suggesting the decrease in state 3
respiration with the combination treatment is mediated by a cLA-dependent
mechanism such as decreased mitochondrial substrate transport (116) or
adenine nucleotide transport.
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The co-treatment was able to increase complex I activity (Fig. 8A), while
decreasing complex II (Fig. 8B) and III (Fig. 8C) activity. The increased complex I
activity (Fig. 8A) and decreased complex II activity (Fig. 8B) seen with the
combination treatment of cLA and nitrite can also be linked to a nitrite dependent
mechanism for complex I and cLA dependent mechanism for complex II activity.
The decrease in complex III activity is dependent on the co-administration of cLA
and nitrite and this could rely on the formation of nitrated-cLA. The decreased
complex III activity could also potential contribute to the decreased state 3
respiration seen with the combination treatment as complex III is the funnel for all
electron flow with the electron transport chain. This would lead to decreased
electron flow and state 3 respiration.
Supplementation with cLA and nitrite in healthy humans leads to an
increase in nitrated-cLA within the plasma (127) and nitration of cLA occurs
within the mitochondria (117). Nitrated fatty acids can post-translationally modify
protein thiols and alter activity (135) and the Rieske subunit of complex III
contains a thiol that has been shown to be S-nitrosylated within mouse cardiac
tissue (134). The unchanged mitochondrial respiratory protein subunits following
the co-treatment with cLA and nitrite (Fig. 9) further suggests a post-translational
modification mechanism for the reduction in complex III activity.
Overall, these results demonstrate that the dietary constituents’ cLA and
nitrite can significantly alter cardiac mitochondrial respiratory and electron
transport chain activity in vivo. Importantly, cLA and nitrite together can decrease
complex III activity, highlighting a complex interaction that occurs following
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consumption of dietary cLA and nitrite that can independently influence cardiac
mitochondrial function.
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CHAPTER IV

CO-TREATMENT OF cLA AND NITRITE IN VIVO ATTENUATES CARDIAC
MITOCHONDRIAL DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
Chapter Overview
Nitrated

fatty

acids,

arising

from

ischemic

cardiac

tissue,

are

cardioprotective in murine models of ischemia reperfusion injury through
mitochondrial dependent mechanisms. cLA is the preferred endogenous
substrate for fatty acid nitration and previous studies have demonstrated that cotreatment with cLA and nitrite preserves cardiac function following MI. In this
study we examine whether the combination treatment of cLA and nitrite alters
mitochondrial function after MI. We demonstrate that the co-treatment with cLA
and nitrite attenuates MI induced mitochondrial dysfunction.
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Introduction
Myocardial infarction (MI) results from blockage of a coronary artery
leading to insufficient blood supply to cardiac tissue, ultimately resulting in
cardiomyocyte death (136) and cardiac dysfunction (137). Normal heart function
relies

on

adenosine

triphosphate

(ATP)

generation

from mitochondria.

Mitochondria produce ATP via the electron transport chain (ETC) to provide
energy for the cell. The ETC shuttles electrons from NADH via NADH ubiquinone
dehydrogenase (Complex I) or FADH2 via succinate dehydrogenase (Complex II)
down the ETC, while pumping protons across the inner mitochondrial membrane
creating an electrochemical gradient. ATP synthase (Complex V) uses free
energy created by the electrochemical gradient to convert ADP to ATP, while
cytochrome c oxidase (Complex IV) transfers electrons from cytochrome c to
oxygen, the final electron acceptor (138). The coupling of electron transport and
pumping of protons is essential for ATP synthesis. Mitochondria produce a basal
rate of reactive oxygen species (ROS), contributed by complex I, II, and III, and
MI results in increased ROS levels (34). The increase in ROS can result in lipid
peroxidation (139) and decreased complex I, III and IV activity (34). Decreased
ETC enzyme activity leads to decreased mitochondrial respiration following
ischemia reperfusion injury (38), indicating that myocardial injury resulting from
MI is associated with mitochondrial dysfunction.
Numerous

studies

have

highlighted

a

role

for

mitochondria

in

cardioprotection including inhibition of mitochondrial permeability transition pore
opening (140, 141), mild mitochondrial uncoupling (142), and mitochondrial
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protein modifications (40, 143). Nitrated fatty acids have been shown to mediate
cardioprotection in models of ischemia-reperfusion injury, via inhibition of p65
(125) and directly at the mitochondrial level via protein modification of adenine
nucleotide translocase-1 (ANT-1) (46).
9Z,11 E-octadecadienoic acid, also known as conjugated linoleic acid or
cLA is an 18:2 fatty acid, which due to the nature of the conjugated double
bonds, can undergo fatty acid nitration in the mitochondria (117). Recent
evidence has shown that a combination treatment of cLA and nitrite is protective
following myocardial infarction (88), overall demonstrating that precursors to fatty
acid nitration mediate protective cell signaling. Based on these findings, this
study investigates how cLA and nitrite impact cardiac mitochondrial function in
vivo and following MI, further evaluating the role of mitochondria in this
cardioprotection.
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Results
To test the hypothesis that co-treatment of cLA and nitrite would mediate
cardioprotection via a mitochondrial mechanism; mitochondrial respiration was
assessed (as outline in Fig. 5) in cardiac mitochondria from C57BL/6J mice
treated with cLA, nitrite and co-treatment prior to and following MI. As treatment
was given prior to MI, mitochondrial respiration was assessed following a 3 day
treatment prior to MI and the combination treatment with cLA and nitrite had no
impact on LEAK (Fig. 10A), state 3 (Fig. 10B) or ETS (Fig. 10C) respiration. The
single treatment of cLA decreased LEAK respiration (Fig. 10A) with no change in
other mitochondrial respiratory parameters (Fig. 10B-D). The single treatment of
nitrite increased both state 3 (Fig. 10B) and ETS (Fig. 10C) respiration and this
increase was reflected in the RCR (Fig. 10D).
Electron transport chain activities from complex I and III following 3 day
co-treatment revealed that the combination treatment of cLA and nitrite
significantly increased complex III activity (Fig. 11B), while complex I activity (Fig.
11A) remained unchanged. Complex I and III activity were unaltered by the
single treatments of cLA and nitrite (Fig. 11A-B). Complex III produces ROS
(144), so to determine if the change in complex III activity increased ROS
generation, hydrogen peroxide levels were measured in cardiac tissue following
3 day co-treatment. Hydrogen peroxide levels were significantly increased
following co-administration of cLA and nitrite and the single treatment of nitrite
(Fig. 11C). Mitochondrial protein subunit expression was also examined following
the 3 day combination treatment and the NDUFB8 protein subunit of complex I
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was significantly decreased following co-treatment (Fig. 12A-B). All other
mitochondrial protein subunits were unaffected for cLA, nitrite or the combination
of cLA and nitrite (Fig. 12A-F).
Following MI, state 3 (Fig. 13B) and ETS (Fig. 13C) respiration
significantly increased while LEAK respiration (Fig. 13A) and the RCR (Fig. 13D)
remained unchanged. Supplementation with cLA was unable to alter MI induced
changes in respiration (Fig. 13A-D). However, the single treatment of nitrite was
able to attenuate MI-induced increases in state 3 (Fig. 13B) and ETS (Fig. 13C)
respiration. Nitrite also increased the RCR (Fig. 13D) following MI. The
combination treatment of cLA and nitrite was able to decrease state 3 (Fig. 13B)
and ETS (Fig. 13C) respiration following MI with no change in LEAK respiration
(Fig. 13A) or the RCR (Fig. 13D).
Electron transport chain activity was assessed to determine if changes in
respiration were linked to alterations in complex I, II, III or IV activity. MI
significantly increased complex I (Fig. 14A) and III (Fig. 14C) activity (Fig. 14A),
while complex II activity was decreased (Fig. 14B). Complex IV activity (Fig. 14D)
was unchanged following MI. cLA treatment further increased complex I activity
(Fig. 14A), decreased complex II activity (Fig. 14B), and had no effect on
complex III (Fig. 14C) or IV (Fig. 14D) activity following MI. Complex I activity
(Fig. 14A) was increased further with nitrite treatment following MI, while complex
III (Fig. 14C) and IV (Fig. 14D) activity remained unaltered with nitrite following
MI; however, nitrite was able to restore complex II activity (Fig. 14B) to control
levels following MI.
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The co-treatment with cLA and nitrite increases complex I activity following
MI (Fig. 14A), had no effect on complex II activity (Fig. 14B), and was able to
attenuate the MI-induced increase in complex III activity (Fig. 14C). Mitochondrial
respiratory protein subunit expression revealed MI increased all respiratory
subunit expression levels (Fig. 15A-F) and cLA, nitrite or co-treatment had no
effect (Fig. 15). MI can cause increases in ROS production (34) and
mitochondrial antioxidants play an important role in balancing ROS production.
MnSOD protein expression was examined following MI and the co-treatment of
cLA and nitrite significantly increased MnSOD protein expression after MI (Fig.
16). Due to the combination treatment decreasing complex III activity and
increasing MnSOD, hydrogen peroxide levels were assessed to determine if
ROS production was changed following MI. Hydrogen peroxide levels are
increased following MI (Fig. 17) and the single treatment of nitrite and cotreatment with cLA and nitrite is able to attenuate the increased hydrogen
peroxide following MI (Fig. 17).
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Figure 10. Mitochondrial respiration remains unchanged following co-treatment with cLA
and nitrite.
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Figure 10. Mitochondrial respiraiton remains unchanged following cotreament with cLA and nitrite. Three day cLA + nitrite treatment has no effect
on LEAK (A, control n=8, cLA n=9, nitrite n=8, cLA + nitrite n=12), state 3 (B,
control n=8, cLA n=7, nitrite n=7, cLA + nitrite n=11) or ETS (C, control n=8, cLA
n=9, nitrite n=8, cLA + nitrite n=11) respiration. cLA decreases LEAK (A)
respiration, while nitrite increases state 3 (B) respiration, ETS (C) respiration and
the RCR (D, control n=8, cLA n=9, nitrite n=6, cLA + nitrite n=11). (*p<0.05
compared to control, One way ANOVA).
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Figure 11. Co-treatment with cLA and nitrite increases complex III activity and nitrite
increases H2O2 levels.
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Figure 11. Co-treatment with cLA and nitrite increases complex III activity
and nitrite increases H2O2 levels.

Complex III activity (B) significantly

increases following three day combination treatment and H2O2 levels significantly
increases following nitrite treatment (C) while complex I actvitity (A) remains
unchanged. (*p<0.05 compared to control, unpaired student t-test, n=4 for all
groups).
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Figure 12. Co-treatment with cLA and nitrite decreases NDUFB8 protein expression.
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Figure 12. Co-treatment with cLA and nitrite decreases NDUFB8 protein
expression. NDUFB8 protein expression (A-B) is significantly decreased
following cLA + nitrite co-treatment. SDHB (A and C), UQCRC2 (A and D),
MTCO1 (A and E), and ATP5A (A and F) protein levels remain unchanged
following cLA, nitrite and co-treatment. (*p<0.05 vs control, One way ANOVA,
n=3 for all groups).
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Figure 13. Nitrite attenuates increases in State 3 and ETS respiration following MI.
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Figure 13. Nitrite attenuates increases in State 3 and ETS respiration
following MI. MI increases state 3 (B, control n=8, MI n=6, MI - cLA n=7, MI Nitrite n=5, MI - cLA + nitrite n=8) and ETS (C, control n=8, MI n=6, MI - cLA n=7,
MI - Nitrite n=5, MI - cLA + nitrite n=8 ) respiration while LEAK respiration (A,
control n=8, MI n=5, MI - cLA n=7, MI - Nitrite n=5, MI - cLA + nitrite n=8) and the
RCR (D, control n=6, MI n=6, MI - cLA n=7, MI - Nitrite n=5, MI - cLA + nitrite
n=8) remain unchanged. Supplementation with nitrite and cLA + nitrite decreases
State 3 (B) and ETS (C) respiration following MI (*p<0.05 compared to control,
#p<0.05 compared to MI, unpaired student t-test).
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Figure 14. Co-treatment with cLA and nitrite attenuates increased complex III activity following
MI.
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Figure 14. Co-treatment with cLA and nitrite attenuates increased complex
III activity following MI. MI increases complex I (A) and complex III (C) activity,
decreases complex II (C) activity and has no effect on complex IV activity (D).
cLA increases complex I (A) activity, decreases II (B) activity and has no effect
on complex III (C) or IV (D) activity following MI. Nitrite increases complex I (A)
activity, restores complex II (B) activity, and has no effect on complex III (C) or IV
(D) activity following MI. Co-treatment with cLA + nitrite increases complex I (A)
activity, decreases complex III (C) activity and has no effect on complex II (B) or
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IV (D) activity following MI. Complex I: (control n=8, MI n=5, MI - cLA n=3, MI Nitrite n=4, MI - cLA + nitrite n=6, *p<0.05 compared to control, #p<0.05
compared to MI, $p<0.05 compared to MI - cLA, MI - cLA + nitrite, One way
ANOVA). Complex II: (control n=4, MI n=6, MI - cLA n=3, MI - Nitrite n=5, MI cLA + nitrite n=6, *p<0.05 compared to control, #p<0.05 compared to MI, MIcLA, and MI- cLA + nitrite, $p<0.05 compared to MI, One way ANOVA). Complex
III: (control n=7, MI n=6, MI - cLA n=3, MI - Nitrite n=5, MI - cLA + nitrite n=6,
*p<0.05 compared to control, #p<0.05 compared to MI and MI- Nitrite, One way
ANOVA). Complex IV: (control n=4, MI n=6, MI - cLA n=3, MI - Nitrite n=5, MI cLA + nitrite n=6).

69

M
I-

M

F

3

2

*

70
*
*

1

0
+

I-

ite

3

itr

M

I-

cL
A

M

+

I-

M

ite

ite

itr

N

I
cL
A
itr

N

I-

M

Fold Change
(normalized to Ponceau)
2

N

ite

N
itr

0.0

IcL
A

0.5

cL
A

1.0

M

1.5

I-

D

I

ol

0.0

M

on
tr

C

N
itr
ite

0.5

M

ol

on
tr

C

*
Fold Change
(normalized to Ponceau)

+

N
itr
ite

1.0

N
itr
ite

ite

itr

cL
A

1.5

+

N

M
I-

A

*

cL
A

+

ite

itr

N

cL

M
I

tr
ol

2.0

N
itr
ite

A

IcL
A

M
I-

M
I-

on

B

M
I-

M

*
*

M
I

tr
ol

2.5

cL

on

I-

cL
A

I

C

Fold Change
(normalized to Ponceau)

*

M
I-

C

M

I-

M

2.0

Fold Change
(normalized to Ponceau)

M

ol

on
tr

C

Fold Change
(normalized to Ponceau)

Figure 15. Treatment with cLA, nitrite or combination increases mitochondrial
respiratory chain protein expression following MI.
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mitochondrial respiratory protein expression following MI. Representative
western blot of NDUFB8, SDHB, UQCRC2, MTCO1, and ATP5A (A) protein
expression from isolated cardiac mitochondria from control, MI, MI - cLA, MI Nitrite and MI - cLA + nitrite. MI- cLA increases SDHB (C), UQCRC2(D), MTCO1
(E) and ATP5A (F) protein expression (*p<0.05 compared to control). MI - Nitrite
and MI - cLA + nitrite increases NDUFB8 (B), SDHB (C), UQCRC2 (D), MTCO1
(E) and ATP5A (F) protein expression (*p<0.05 compared to control, #p<0.05
compared to MI - cLA, MI - Nitrite, unpaired student t-test).
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Figure 16. Treatment with cLA + nitrite increases MnSOD protein expression
following MI.
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Figure 16. Treatment with cLA + nitrite increases MnSOD protein
expression following MI. Representative western blots of MnSOD (A) protein
expression from isolated cardiac mitochondria from control (n=4), MI (n=5), MI cLA (n=4), MI - Nitrite (n=5) and MI - cLA + nitrite (n=6). Co-treatment with cLA
and nitrite increases MnSOD protein expression following MI (B) (*p<0.05
compared to control, unpaired student t-test).
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Figure 17. Nitrite decreases H2O2 levels following MI.
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Figure 17. Nitrite decreases H2O2 levels following MI. H2O2 levels increase
following MI (n=4), MI - cLA (n=3) and MI - Nitrite (n=4) (*p<0.05 compared to
control, n=4, One way ANOVA). However, supplementation with nitrite or cLA +
nitrite (n=7) decreases H2O2 production following MI (#p<0.05 compared to MI
and MI- cLA, One way ANOVA).
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Discussion
Recent evidence has shown that co-treatment with cLA and nitrite
mediates protection against MI (88). cLA undergoes nitration in vivo (117) and
nitrated fatty acids mediate protection against ischemic injury by mitochondrial
dependent mechanisms (47, 126). Cardiac mitochondrial respiration and
respiratory complex activity was assessed prior to and following MI with cotreatment of cLA and nitrite to determine whether mitochondria played a role in
this protection. The major findings from this study reveal that co-treatment with
cLA and nitrite is able to attenuate MI-induced increases in state 3 respiraiton
(Fig. 13 B), ETS respiration (Fig. 13C), complex III activity (Fig. 14C) and
hydrogen peroxide levels (Fig. 17), while increasing MnSOD protein expression
following MI (Fig. 16).
The combination treatment was administered 3 days prior to MI and
mitochondrial respiration was performed following 3 day treatment to determine
mitochondrial changes ocurring prior to MI. The combination treatment of cLA
and nitrite did not alter mitochondrial respiration parameters including: LEAK
respiration (Fig. 10A), state 3 respiration (Fig. 10B), ETS respiration (Fig. 10C)
and the RCR (Fig. 10D). These results indicate that mitochondrial respiration is
functional with the co-treatment prior to MI.
The co-treatment prior to MI was able to significantly increase complex III
activity (Fig. 11B) without changing complex I activity (Fig. 11A). The
combination treatment did decrease NDUFB8 protein expression (Fig. 12A and
B) without changing SDHB, UQCRC2, MTCO1 and ATP5A protein levels (Fig. 12
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A-F). The NDUFB8 is not involved in the catalytic activity of complex I, thereby
potentially explaining the unaltered complex I activity seen with the combination
treatment despite decreased NDUFB8 protein levels.
As complex I and III can produce ROS (38), hydrogen peroxide levels
were measured to determine if the increase in complex III activity correlated with
an increase in ROS. Hydrogen peroxide levels were increased with both nitrite
and the combination of cLA and nitrite (Fig. 11) indicating nitrite is increasing
hydrogen peroxide levels independent of changes in complex III activity.
However, the hydrogen peroxide was measured in cardiac tissue homogenate
thereby the source of hydrogen peroxide could differ between the nitrite
treatment and co-treatment as nitrite can increase NADH oxidase 2 (NOX2), a
mediator of non-mitochondrial ROS generation (107).
Following MI, state 3 respiration (Fig. 13B) and ETS respiration (Fig. 13C)
increased without changing LEAK respiration (Fig. 13A) or the RCR (Fig. 13D).
The increases in respiration following MI are in contrast to reports in the literature
in which MI is associated with mitochondrial dysfunction (34). The differences
observed in this study may be related to the time point, as mitochondrial
respiration was assessed ten days after MI and most studies evaluate
mitochondrial function within a short time period. Additionally, this time period
allows for adaptive cell signalling to compensate for mitochondrial dysfunction
and the increased mitochondrial respiratory protein levels following MI (Fig. 15AF) indicates an upregulation in electron transport chain protein expression to
compensate for mitochondrial dysfunction.
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The single treatment of cLA was unable to alter changes in mitochondrial
respiration induced by MI. However, single treatment of nitrite and combination
treatment of cLA and nitrite was able to attenuate increased state 3 respiration
(Fig. 13B) and ETS respiration (Fig. 13C) following MI. The reliance on nitrite to
reduce mitochondrial respiration following MI in the single and combination
treatment could be attributed to nitrite’s conversion to nitric oxide. Nitrite can
undergo reduction to nitric oxide under conditions of hypoxia by deoxygenated
hemoglobin (62), deoxygenated myoglobin (63), and low pH (145), all conditions
that prevail following MI. Nitric oxide can inhibit mitochondrial respiration (81)
demonstrating that the nitrite mediated decreases in respiration observed
following MI could be linked to nitrite’s conversion to nitric oxide.
MI increased complex I activity (Fig. 14A) and cLA, nitrite and the
combination treatment further increased complex I activity (Fig. 14A). The
increased complex I activity following MI is contrary to literature in which cardiac
injury decreases complex I activity (34). The observed differences in this study
could be due to the time point in which complex I activity was assessed (10 days)
or the area of cardiac tissue from which mitochondria were isolated (border zone
vs whole heart). Both the cLA and co-treatment of cLA and nitrite are significantly
higher than the MI and MI – Nitrite group indicating cLA is the mediator of this
increase. cLA has been shown to increase ROS in macrophages (105), oxidative
stress in rat cardiac tissue (106), and 8-iso-prostaglandin F2α urine levels in
obese males (104). cLA has also been shown to induce cardiac dysfunction in
aging by uncoupled eNOS (107). These results suggest that cLA may exacerbate

76

oxidative stress conditions such as MI, aging and obesity. The increased
complex I activity observed with cLA following MI may provide a mechanistic link
between cLA and the detrimental effects observed with cLA in oxidative stress
conditions.
Complex II activity was significantly decreased following MI (Fig. 14B) and
neither cLA nor the co-treatment was able to restore complex II activity after MI
(Fig. 14B). Nitrite administration restored complex II activity following MI (Fig.
14B); however, the restoration of complex II activity is not necessary to mediate
cardioprotection as nitrite was unable to provide protection against MI (88).
MI significantly increased complex III activity (Fig. 14C) and the single
treatments of cLA and nitrite were unable to decrease MI induced upregulation of
complex III activity. The increased complex III activity following MI differs from
literature reports in which cardiac injury decreases complex III activity (34) and
this is most likely due to the border zone of the infarct being used for cardiac
mitochondrial complex III activity as opposed to whole heart.
The combination of cLA and nitrite was able to attenuate the increased
complex III activity following MI (Fig. 14C). The decreased complex III activity
mediated by cLA and nitrite could rely on the formation of nitrated cLA since cLA
undergoes nitration within mitochondria (117) and formation of nitrated fatty acids
increases following ischemic injury (125). The Reiske subunit of complex III
contains a thiol that can be S-nitrosylated (134) and the alkanine conditions
within mitochondria promote nitro-fatty acids to react with thiols (135). These
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conditions favor a mechanism by which nitrated cLA is able to post-translationally
modify complex III, thereby decreasing its activity following MI.
High levels of ROS generated by complex I and III during MI can result in
cardiac damage and upregulated complex I and III activity following MI correlated
with increases in hydrogen peroxide after MI (Fig. 17). Supplementation with
nitrite and the combination of cLA and nitrite was able to attenuate the increased
hydrogen peroxide levels (Fig. 17), while the single treatment of cLA was unable
to decrease the levels (Fig. 17). The decreased complex III activity following cotreatment of cLA and nitrite could explain the decreased hydrogen peroxide
levels generated after MI; however the single treatment of nitrite also decreased
the hydrogen peroxide levels. An alternative explanation could be attributed to
nitrite derived NO reaction with superoxide thereby reducing the pool of
superoxide that can be converted to hydrogen peroxide.
Overall, these results suggest the cardiac protection afforded by the
combination treatment of cLA and nitrite may be in part mediated by attenuation
of MI induced increases in mitochondrial respiration, complex III activity and ROS
generation.
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CHAPTER V

CARDIAC MITOCHONDRIAL FUNCTION AND AGING
Chapter Overview
Aging and ischemic injury share similarities of cardiac mitochondrial
dysfunction resulting in decreased heart function. cLA and nitrite are found within
dietary foods such as runimant meat and green leafy vegetables. Nitrite and cLA
have both been associated with cardiovascular health and appear to mediate
these effects through mitochondria. However, the impact of nitrite and cLA on
cardiac mitochondria in aging is unknown. Recent evidence has shown that cLA
supplementation in aged mice decreased cardiac function and supplementation
of nitrite was able rescue this dysfunction. This study examines the impact of
aging on cardiac mitochondrial function and examines whether co-treatment with
cLA and nitrite rescues cardiac mitochondrial dysfunction. This study reveals
there is an age dependent decline in cardiac mitochondrial function and
supplementation with the combination treatment of cLA and nitrite was unable to
rescue aged related cardiac mitochondrial function.
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Introduction
Aging is associated with cellular changes ultimately resulting in declines in
cellular function (146). The development of cardiovascular disease and risk for
MI increases with age (146). Aging is associated with increased oxidative stress
(147) and mitochondrial driven ROS contributes to this elevated oxidative stress
condition. Aging results in diminshed mitochondrial function (148-150) thereby
limiting the ATP pool needed to maintain normal cardiovascular function.
Mitochondria also play an important role in mediating cardioprotective effects
against MI (32); however, these protective effects are lost in aging (42). One of
the theories behind this loss of cardioprotection is loss of mitochondrial function
(42), so strategies to improve mitochondrial function in aging could restore
mitochondrial mediated protection against MI. Nitrite and cLA are dietary
consitutents that are known to influence mitochondrial function (73, 115) and
mediate cardioprotection (88). However, it is unknown if these effects carry over
to aged mitochondria. This study was undertaken to determine whether cLA,
nitrite or the combination is able to reverse aged cardiac mitochondrial
dysfunction.
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Results
Mitochondrial respiration assessed in 10 and 33 month old revealed an
aged dependent decline in mitochondrial respiratory capacity. Ten-month old
mice displayed a significant decrease in state 3 respiration (Fig. 18B) with a
concurrent decrease in the RCR (Fig. 18D). LEAK respiration (Fig. 18A) was not
decreased in 10 month old mice. The ETS respiration (Fig. 18C) appeared to be
decreased, though it was not statistically significant. When mice were aged to 33
months, there was a significant decline in both LEAK (Fig. 18A) and state 3 (Fig.
18B) respiration compared to 8-12 week old mice. The ETS respiration was
noticeable decreased in 33 month old mice (Fig. 18C), but was not statistically
significant. The RCR (Fig. 18D) was not changed. To assess whether
supplementation with cLA and nitrite could rescue aged related declines in
mitochondrial function, 10 month old mice were treated with cLA, nitrite or the
combination treatment of cLA and nitrite for 6 weeks after which mitochondrial
function was assessed. Treatment with cLA, nitrite or co-treatment did not alter
LEAK respiration (Fig. 19A) or rescue decreased state 3 respiration (Fig. 19B).
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Figure 18. Aging induces cardiac mitochondrial dysfunction.
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Figure 18. Aging induces cardiac mitochondrial dysfunction. 10 month old
mice have reduced state 3 (B) respiration, ETS respiration (C) and RCR (D),
while LEAK respiration (A) remained unchanged. LEAK (A), state 3 (B) and ETS
(C) respiration was decreased in 33 month old mice, while the RCR (D) remained
unchanged. (*p<0.05 vs 3 month, unpaired student t-test, 3 month n=4, 10 and
33 month n=3).

82

Figure 19. Treatment with cLA, nitrite, or in combination does not attenuate aged related
decline in cardiac mitochondrial function.
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Figure 19. Treatment with cLA, nitrite or in combination does not attenuate
aged related decline in cardiac mitochondrial function. Six week treatment
with cLA, nitrite and cLA + nitrite was unable to rescue reduced state 3
respiration (B), ETS respiration (C) or the RCR (D). LEAK (A) respiration was
unchanged following treatment with cLA, nitrite or cLA + nitrite. (*p<0.05 vs
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control, One way ANOVA, control n=4, control - 10 month, cLA - 10 month, Nitrite
- 10 month, and cLA + nitrite - 10 month n=3).
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Discussion
Age is a significant risk factor for cardiovascular disease and subsequent
complications such as MI (151). The development of cardiovasuclar disease in
aging is associated with mitochondrial dysfunction and increased oxidative stress
(147). Mitochondrial generated ATP is essential for maintaining normal
cardiovascular health and plays a protective role against MI (32). However, with
aging, the protective role of mitochondria against MI is lost (42) and this is
thought to be associated with a decline in mitochondrial function. As
demonstrated in this study, mice aged to 10 or 33 months displayed decreased
mitochondrial function (Fig. 18). The 33 month-old mice had significantly
decreased LEAK (Fig. 18A) and state 3 (Fig. 18B) respiration, while the 10
month-old mice only had a decrease in state 3 respiration (Fig. 18B).
The decrease in state 3 respiration but not LEAK respiration for the 10
month-old mice suggests that under low energy demand the ETS is able to
effectively transport electrons down the ETS. However, under high energy
demands requiring production of ATP, the ETS is unable to meet these
demands, resulting in supressed state 3 respiration. As aging continues, the ETS
further declines in electron transporting capacity, resulting in the diminished
LEAK and state 3 respiration observed in the 33 month-old mice. This can result
in over production of mitochondrial generated ROS (152) coupled with reduced
antioxidant defenses (153), ultimately resulting in damage to the oxidative
phosphorylation proteins within the ETS

and leading to mitochondrial

dysfunction. The ETS was reduced in both 10 and 33 month old-mice; however,
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it was not statistically significant. This is likely due to the low number of mice per
group and over titration of the mitochondrial uncoupler resulting in greater
variability within the ETS respiration. Overall, these data shows there is an age
dependent decline in mitochondrial function.
Nitrite is considered an endogenous reservoir of NO that can be obtained
from the diet by consuming green leafy vegetables or beet juice. Nitrite has been
shown to increase mitochondrial function in adipocytes (83) and modulate
cardiac mitochondrial function under injury settings (51); however the effect of
nitrite on aged cardiac mitochondrial function is unknown. This study assessed
whether nitrite supplementation could rescue aged related cardiac mitochondrial
dysfunction and found that it could not (Fig. 19). These results suggest that nitrite
is unable to upregulate mitochondrial function either directly at the level of
mitochondria or upstream such as upregulated activation of AMPK (83).
Interestingly, nitrite supplemenation in aged mice treated with cLA was able to
rescue cardiac left ventricular dysfunction (107). This was mediated by restoring
eNOS dimerization and NO signaling. These results coupled with nitrite being
unable to rescue aged mitochondrial function, suggest the more prominent role of
nitrite in aging is to restore NO signaling which is lost within the vasculature
during aging (107, 147).
cLA supplementation in aged mice resulted in worsening left ventricular
cardiac function (107) and decreased mitochondrial function with cLA could
explain this observation. Mitochondrial function from aged mice treated with cLA
did not result in decreased mitochondrial function (Fig. 19A-D). Therefore, the
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detrimental effects seen with cLA in aged mice is not due to diminishing cardiac
mitochondrial function.
The increased oxidative and nitrative stress conditions associated with
aging (147) favor the formation of nitrated fatty acids (93) and nitrated fatty acids
(46, 125) along with precursors to fatty acid nitration (cLA and nitrite) are
cardioprotective. Supplementation of cLA and nitrite in aged mice was unable to
reverse the aged dependent decline in mitochondrial function (Fig. 14). These
results suggest that a potential protective role of nitrated fatty acid or precursors
to fatty acid nitration is not mediated through restoration of mitochondrial
function. cLA and nitrite can upregulate HO-1 gene expression (88, 117)
representing an alternative pathway for cardiac protection in aging.
Overall, these results demonstrate that cardiac mitochondrial function
declines with age and supplementation with cLA, nitrite, or co-treatment is unable
to rescue this aged related mitochondrial dysfunction.

87

CHAPTER VI
FUTURE DIRECTIONS AND CONCLUSIONS
Conclusion
Cardiovascular disease is the leading cause of mortality within the United
States with MI contributing the majority of morbidity. Clinical intervention to
lessen cardiac injury following MI is limited, highlighting a need for further
research and development of new therapeutic approaches. Conjugated linoleic
acid and nitrite represent dietary constituents that may be utilized to lessen
cardiac injury as the combination of these dietary substances preserves cardiac
function in a murine model of MI. Due to the essential role of mitochondria in
maintaining

normal

cardiac

function

and

recent

evidence

detailing

a

mitochondrial mechanism for nitrated fatty acids, this study was undertaken to
determine how precursors to fatty acid nitration (cLA and nitrite) impacted cardiac
mitochondrial function. The first part of this study revealed that a ten-day
combination treatment of cLA and nitrite decreases state 3 and ETS respiration,
along with complex II and III activity. The combination treatment also increased
complex I activity. These results reveal that in combination, cLA and nitrite can
impact cardiac mitochondrial function in vivo.
Next, cardiac mitochondrial function was assessed under two conditions
of injury or stress, MI and aging. We then assayed whether co-treatment with
cLA and nitrite was able to rescue mitochondrial dysfunction during these
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conditions. In the setting of MI, the co-treatment was able to attenuate MI
induced increases in state 3 respiration, complex III activity and hydrogen
peroxide levels. These results reveal a potential mitochondrial mechanism for the
cardioprotection mediated by co-treatment with cLA and nitrite. Cardiac
mitochondrial function was suppressed following aging and the combination
treatment with cLA and nitrite was unable to restore cardiac mitochondrial
function. These results reveal that the mitochondrial effects mediated by cLA and
nitrite are lost in a murine model of aging. Taken together, this study
demonstrates that a combination treatment of cLA and nitrite is able to modulate
cardiac mitochondrial function in vivo and reverse MI, but not aging- induced
mitochondrial dysfunction.

Future Directions
cLA
This study revealed that cLA was able to repress cardiac mitochondrial
function and decrease complex II activity in vivo. These results suggest cLA
could potentially be able to alter mitochondrial metabolism. However, the
mechanism leading to this outcome is unknown. Due to the numerous upstream
cellular signaling linked to cLA (101) that can impact mitochondrial function, it is
necessary to delineate whether cLA is functioning upstream of mitochondria or
directly at the level of mitochondria. Incubation of isolated cardiac mitochondria
with cLA followed by mitochondrial respiration will reveal if cLA mediates
decreases in mitochondrial respiration directly at the level of mitochondria. Co-
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incubation of cLA with etomoxir (154), an inhibitor of fatty acid beta-oxidation, on
isolated cardiac mitochondria will reveal whether full length cLA or a downstream
oxidation product is necessary to mediate cLA effects on mitochondria. Transport
of glutamate, malate, and ADP into mitochondria is necessary for mitochondrial
respiration as the isolation of mitochondria depletes endogenous substrates. The
cLA mediated decrease in state 3 respiration following cLA treatment suggests
transport of ADP into in mitochondria is limited. ANT-1 is responsible for the
transfer of ADP into the mitochondria and ATP out of mitochondria (155). The
measurement of ANT-1 activity in isolated cardiac mitochondria from mice
treated with cLA will be carried out using a magnesium sensitive dye, Magnesium
Green. This will indicate if ANT-1 activity is decreased following cLA treatment
and provide a potential mechanism by which cLA decreases mitochondrial
respiration.
The mechanism for the cLA mediated decrease in complex II activity will
be examined by assessing the activity of malate dehydrogenase. Malate
dehydrogenase converts malate to oxaloacetate, which is a potent inhibitor of
complex II activity. The cis-9 trans-11 isomer of cLA has been shown to increase
malate dehydrogenase activity in the liver of rats (156) and high levels of
oxaloacetate following cLA treatment may lead to decreased complex II activity.

Nitrite
This study revealed that nitrite was able to increase complex I activity in
vivo under baseline conditions. Complex I has been shown to undergo S-
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nitrosylation by an NO donor on cysteine 39 within the ND3 subunit under
conditions of ischemic injury (40). This S-nitrosylation was able to transiently
inhibit complex I activity and removal of this modification restored complex I
activity (40). Interestingly, this modification is not seen under normoxic conditions
with the NO donor. However, S-nitrosylation of cysteine 344 within the 75 kDa
subunit is found under normoxic conditions (40). Mass spectrometry analysis
examing S-nitrosylation of cysteine 344 within the 75 kDa subunit of complex I
following nitrite treatment would correlate increased complex I activity with an
increase in this modification; providing a link between nitrite treatment and
increased complex I activity.

Co-treatment of cLA and nitrite
The major findings of this study reveal that the combination treatment of
cLA and nitrite was able to decrease complex III activity under baseline
conditions and attenuate MI induced increases in complex III activity. Nitrated
fatty acids can form adducts with free thiols via Micheal addition thereby altering
protein activity (135). The cytochrome b-c1 complex subunit I, II and Rieske
subunit all contain cysteiene residues that can be S-nitrosylated (134) and these
residues may also undergo Micheal addition with nitrated fatty acids. Mass
spectrometry analysis for nitrated cLA adducts to cysteine 69 and 410 within
cytochrome b-c1 complex subunit 1, cysteine 192 within cytochrome b-c1
complex subunit 2 and cysteine 51 with cytochrome b-c1 subunit Rieske will
provide insight into whether nitrated cLA adducts to thiols within complex III.
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Alternatively, linoleic acid is a major component of cardiolipin which is essential
for complex III activity and mitochondrial supercomplex formation. Lipid
peroxidation of linoleic acid within cardiolipin has been associated with
decreased complex III activity and super complex formation (157). Due to
structural similarities between cLA and lineolic acid, the nitration of cLA may
mimic the lipid peroxidation effect of linoleic acid leading to the decreased
complex

III

activity

via

supercomplex

formation.

The

assessment

of

supercomplex formation by blue native PAGE following cLA and nitrite treatment
would provide insight into mitochondrial structural architecture changes that
regulate complex III activity.
Additionally, the assessment of hydrogen peroxide levels in freshly
isolated mitochondria following MI would yield a stronger link between decreased
complex III activity and hydrogen peroxide levels. The addition of antimycin A to
isolated mitochondria that have undergone MI would decrease elevated complex
III activity thereby lowering hydrogen peroxide levels. This would provide a
mechanistic link between complex III activity and hydrogen peroxide levels
following MI.
The combination treatment of cLA and nitrite increases protein expression
of HO-1, and HO-1 is a Nrf2 regulated gene. The regulation of complex III activity
and hydrogen peroxide levels could potentially play a role in activating Nrf2 via
redox dependent inactivation and degradation of KEAP1, the negative regulator
of Nrf2. Examining nuclear translocation of Nrf2 in cardiac tissue of mice
following co-treatment of cLA and nitrite would further the mechanism of HO-1
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mediated cLA and nitrite cardioprotection to include mitochondrial derived ROS
via altered complex III activity.
The combination of cLA and nitrite could also be mediating protective
against MI via several alternative pathways including shifting from oxidative
phosphorylation to glyolytic metabolism during MI and decreasing necrosis to
prevent infacrt expansion. During ischemia reperfusion injury due to the lack of
oxygen cells undergo a shift in metabolism and rely on glycolysis for ATP
production (158). As the combination treatment decreases complex II and III
activity (Fig. 8) this could limit electron flow from the TCA cyle and beta oxidation
into the electron transport chain leading to reductions in ATP. The shift to
glycolysis may allow cells an apadative phase to increase ATP production via
glycolysis thereby cells are more likey to survive an ischemic insult. To determine
if cLA and nitrite does shift cells to a more glycolytic phenotype, the activity of
phosphofructokinase will be assayed. Phosphofructokinase is the first committed
step in glycolysis and would provide insight into the rate of glycolysis.
Necrosis occurs following depletion of ATP and results in cell death (159).
As the combination treatment of cLA and nitrite could potential increase ATP
production via glycolysis, this may provide a link to prevent necrosis during MI.
By maintaining ATP levels via glycolysis during ischemia this would prevent cells
from undergoing necrosis and reduce secondary inflammtory responses that
occur after cell necrosis. To determine if cLA and nitrite is decreasing necrosis,
the release of two necrosis specific markers will be assessed: peptidylprolyl
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isomerase A and non-chromatin-binding high mobility group protein B1 (160)
following MI.
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